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ZUSAMMENFASSUNG 
Die Alzheimer Krankheit (Alzheimer’s disease, AD) gehört zu den häufigsten altersabhängigen 
Demenzerkrankungen mit mehreren Millionen Betroffenen weltweit. Sie ist durch eine schnell 
fortschreitende Abnahme der kognitiven Fähigkeiten und durch Neurodegeneration 
gekennzeichnet. Histopathologisch ist AD durch das Auftreten von amyloiden (Aβ) Plaques, 
Neurofibrillen und einer neuronalen Entzündung charakterisiert. Die in den Plaques vorhandenen 
Aβ Peptide entstehen aus der proteolytischen Verarbeitung des amyloiden Vorläufer Proteins 
(amyloid precursor protein, APP). Mutationen in Genen von APP oder Proteinen, die für dessen 
Verarbeitung verantwortlich sind, gelten als Hauptursache für die früh auftretende, familiäre 
Form von AD. Aus diesem Grund hat sich die Forschung lange auf die APP Verarbeitung und 
die Aβ Ablagerung fokussiert. Jedoch zählt die überwiegende Mehrzahl von Fällen zur 
sogenannten sporadischen Form von AD, dessen genaue Ursache nach wie vor unklar ist. 
Verschiedene Hinweise deuten darauf hin, dass sich die pathophysiologischen Mechanismen, die 
der familiären und sporadischen AD zugrunde liegen, unterscheiden. Verschiedene genetische, 
umweltbedingte und Lebensstyl-abhängige Risikofaktoren für die sporadische AD wurden 
identifiziert, von welchen angenommen wird, dass sie synergetisch für den Ausbruch dieser 
multifaktoriellen Erkrankung verantwortlich sind. Bis anhin gab es jedoch kein Tiermodel für die 
sporadische AD. Unsere Forschungsgruppe hat jedoch beobachtet, dass eine maternale 
Immunstimulation während der späten Schwangerschaft gefolgt von einer zweiten Stimulation in 
den adulten Nachkommen einen altersbedingten, AD-ähnlichen Phänotyp in Wildtypmäusen 
verursacht. Dieses sogenannte „double hit“ Mausmodell gehört zu den ersten Versuchen jene 
spezifischen Veränderungen im Hirn zu induzieren, die es ermöglichen sollen die Mechanismen 
der sporadischen AD zu untersuchen.  
In den letzten Jahrzehnten kamen Hinweise zum Vorschein einer Komorbidität von AD und 
Epilepsie. In beiden Krankheiten wurden beispielsweise Netzwerkanomalien infolge einer 
Dysfunktion von Interneuronen nachgewiesen, wobei diese im Falle der AD den für die AD 
charakteristischen Symptomen vorauszugehen scheinen. Neuronale Entzündung, welche in 
beiden Erkrankungen vorkommt, so vermuten einige, stellt möglicherweise ein Bindeglied 
zwischen den beiden Erkrankungen dar. 
Das Hauptziel dieser Doktorarbeit ist den Effekt von Netzwerkanomalien in der Entwicklung der 
AD Pathologie und einen neuentdeckten Mechanismus der Verstärkung inhibitorischer 
Übertragung zu untersuchen. Letzteres könnte möglicherweise direkten Einfluss haben auf die 
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Pathophysiologie von Erkrankungen des zentralen Nervensystems (ZNS), wie beispielsweise die 
AD.  
Das erste Projekt untersucht den Beitrag von Kainate (KA)-induzierten Anfällen auf die AD-
ähnliche Pathologie im „double hit“ Model der sporadischen AD und dem ArcticAβ Maus Model 
der familiären AD. Die unilaterale Injektion von KA in den Hippocampus von adulten Mäusen 
ist ein gut etabliertes Model der Temporallappen Epilepsie. Die Injektion verursacht eine Läsion, 
welche charakterisiert ist durch den Verlust von Zellen im Hilus, CA1, und in Teilen von CA3, 
einer Dispersion von Körnerzellen und einer exzessiven, neuronalen Entzündung. Die ersten 24 
Stunden nach der Injektion sind gekennzeichnet durch den Status epilepticus mit konvulsiven 
Anfällen, gefolgt von einer zweiwöchigen, anfallsfreien Latenzphase worauf spontan 
wiederkehrende Anfälle (spontaneous recurrent seizures, SRS) auftreten für die restliche 
Lebensdauer des Tieres.  
Zunächst haben wir getestet, ob KA-induzierte epileptische Anfälle in pränatal 
immunstimulierten Mäusen die zweite Immunstimulation des „double hit“ Models ersetzen kann 
und eine AD-ähnliche Pathologie hervorruft. Ferner wollten wir wissen, ob das Auftreten von 
Anfällen ausreicht die Entwicklung einer AD-ähnliche Pathologie nach einer Immunstimulation 
im erwachsenen Alter zu begünstigen. Immunohistochemische Analysen der beiden Kohorten im 
Alter von 9 und 15 Monaten wiesen jedoch keine Anzeichen einer AD Pathologie auf. Allerdings 
haben sich Zweifel erhoben über den Erfolg der Immunstimulation, als nicht-epileptische 
Kontrollmäuse keine Anzeichen einer chronischen Entzündung nach einer Immunstimulation 
aufwiesen.  
Gleichermassen haben wir den Effekt von KA-induzierten Anfällen auf die AD-ähnliche 
Pathologie im ArcticAβ Maus Model der familiären AD untersucht. Bereits vor dem Auftreten 
der Plaque Pathologie waren diese Mäuse sehr anfällig auf KA, weshalb fürsorglich Diazepam 
nach der Operation verabreicht wurde um eine unmittelbare Mortalität zu verhindern. 
Nichtdestotrotz, die Vulnerabilität von ArcticAβ Mäuse gegenüber Anfällen blieb über diese 
initiale Phase hinaus bestehen und die überwiegende Mehrheit dieser KA-injizierten AD Tiere 
starb in den Folgemonaten. Diejenigen ArcticAβ Mäuse, welche die 9 Monate überlebten, 
wiesen eine vergleichbar milde Läsion auf, wobei sich das Läsionsmuster ausschliesslich auf 
einen Zellverlust in CA1 beschränkte. Überraschenderweise war dieser ipsilaterale Hippocampus 
frei von Aβ Plaques. Der fehlende Unterschied zwischen nichtinjizierten und injizierten 
ArcticAβ Mäuse hinsichtlich der Ablagerung von Plaques im Neokortex liess uns schlussfolgern, 
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dass die KA Injektion lokale Veränderungen nach sich zieht, die die Bildung von Plaques 
entweder verhindert oder zumindest verzögert.  
Frühere Studien haben gezeigt, dass eine Unterdrückung der adulten Neurogenese den Effekt 
von KA verstärkt. Ferner ist bekannt, dass viele Mausmodelle der familiären AD eine 
Veränderung in der adulten Neurogenese aufweisen. Aus diesem Grund haben wir die adulte 
Neurogenese der ArcticAβ Mäusen charakterisiert im Hinblick auf einen möglichen 
Erklärungsansatz für den Ursprung der Sensitivität dieser Mäuse auf KA. Im Vergleich zu 
Wildtypen zeigen die unreifen, adult-geborenen Neuronen von ArcticAβ Mäusen eine reduzierte 
dendritische Verästlung und Dornendichte (d.h. Dichte von Spines). Eine Beeinträchtigung in der 
Reifung solcher der adulten Neurogenese entstammenden Neurone kann zur Folge haben, dass 
diese inadäquate in das hippocampale Netzwerk integriert werden. Es ist bekannt, dass diese 
adult-geborenen Neurone in ihrer Gesamtheit einen inhibitorischen Effekt auf das Gyrus 
dentatus-CA3 Netzwerk ausüben und somit lässt sich vermuten, dass sie potentiell zur 
Sensitivität der ArcticAβ Mäuse auf KA beitragen. 
Eine Fehlfunktion von Interneuronen wurde häufig beobachtet in der AD. GABAerge 
Interneurone orchestrieren die Aktivität von Netzwerkoszillationen und/oder kontrollieren die 
Entladungsrate und das Entladungsmuster von Hauptzellen. Der zweite Hauptteil dieser 
Doktorarbeit fokussiert auf einen neuentdeckten Mechanismus der Verstärkung inhibitorischer 
Übertragung in Sternzellen des Kleinhirns. Es konnte gezeigt werden, dass eine Erhöhung der 
mitochondrialen reaktiven Sauerstoffspezies (mitocondrial reactive oxygen species, mROS), 
beispielsweise infolge eines hohen metabolischen Bedarfs der Zelle, als protektiver Feedback 
Mechanismus fungieren kann, indem zusätzliche GABAARs an die Synapse rekrutiert werden. 
Interessanterweise haben diese rekrutierten Rezeptoren eine spezifische Zusammensetzung von 
Untereinheit, sowie eine unterschiedliche Zerfallskinetik im Vergleich zu der überwiegenden 
Mehrheit der ansässigen Rezeptoren. Unsere Resultate zeigten, dass eine wiederholte 
hochfrequente Stimulation der Inputfasern eine Wiederauferweckung (engl., un-silencing) eines 
bestimmten Vorrats von GABAARs und eine Rekrutierung an die Synapse zur Folge hat. Der 
genaue Mechanismus und die Signalkaskaden, die dieser Verstärkung der GABAergen 
Übertragung zugrunde liegen, sind nach wie vor unbekannt. Jedoch ist zu vermuten, dass ein 
Zusammenbruch eines solchen protektiven Feedbackmechanismus zu einer anomale Aktivität 
von Interneuronen oder sogar deren Degeneration infolge oxidativen Stresses führen könnte. 
Dies hätte wiederum einen grossen Einfluss auf das gesamte Netzwerk. Sollte sich bestätigen, 
dass dies ein allgemeiner Mechanismus ist, den man in verschieden Typen von Interneuronen 
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findet, bestände die Möglichkeit, dass eine fehlerhafte Wiederauferweckung von GABAergen 
Synapsen durch mROS Bestandteil der Pathophysiologie verschiedenster ZNS Krankheiten ist, 
inklusive der AD. 
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ABSTRACT 
Alzheimer’s disease is one of the most common age-related dementias affecting millions of 
people worldwide. Characteristic features of this disorder are progressive loss of cognitive 
abilities and neurodegeneration. Histopathological hallmarks of AD include formation of 
amyloid beta (Aβ) plaques, neurofibrillary tangles and neuroinflammation. Aβ peptides arise 
from proteolytic processing of amyloid precursor protein (APP).  Mutations in genes encoding 
APP and its processing machinery cause familial early-onset AD. For a long time the focus of 
AD research was on APP processing or Aβ deposits. However, the vast majority of AD cases are 
sporadic and so far there is no clear answer to what triggers the pathology. It is likely that 
pathophysiological mechanisms leading to familial and sporadic AD are different. Various 
genetic, environmental and lifestyle risk factors have been identified for sporadic AD, suggesting 
that it is most likely a multifactorial disorder that develops when a number of factors converge. 
So far, there is no animal model of sporadic AD. However, our lab has observed that a maternal 
immune challenge at late gestation followed by a second immune challenge in adult offsprings 
triggers age-dependent development of AD-like pathology in wild-type mice. This “double hit” 
model is a first attempt to induce brain alterations relevant for exploring the mechanisms of 
sporadic AD.  
In the last decade evidence of comorbidity of AD and epilepsy has emerged. Network 
abnormalities due to interneuron dysfunction are common in both conditions and in case of AD 
they appear prior the onset of typical symptoms. Neuroinflammation, which also occurs in both 
diseases, is a possible link between the two conditions. 
The overall goal of this thesis is to study the effects of network abnormalities on development of 
AD pathology and to investigate a newly described strengthening mechanism of inhibitory 
transmission, which could potentially be implicated in the pathophysiology of CNS diseases, 
including AD.  
The first project focused on the contribution of kainic acid (KA)-induced seizure activity to AD-
like pathology in the sporadic “double hit” and familial ArcticAβ AD mouse models. Unilateral 
intrahippocampal injection of KA in adult mice is a well-established model of temporal lobe 
epilepsy. The injection causes a lesion characterized by the loss of hilar cells, CA1 and partly 
CA3, dispersion of granule cell layer and extensive neuroinflammation. During the first 24 hours 
post-injection, status epilepticus with convulsive seizures occur, followed by a two-week long 
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seizure-free latent phase after which spontaneous recurrent seizures (SRS) arise for the life-time 
of the animal.  
First, we tested whether KA-induced epileptic seizures in prenatally immune-challenged mice 
could substitute the second immune insult and lead to AD-like pathology.   
Our next question was to understand whether a brain with already induced seizure activity can 
develop AD-like pathology following an immune insult in adulthood. Immunohistochemical 
analysis of both cohorts of mice did not show any signs of AD pathology at the age of 9 and 15 
months. However, control non-epileptic mice did not exhibit signs of chronic inflammation after 
the immune challenge, raising doubts about its effectivity.  
We went on to analyze the effects of KA induced seizures on AD-like pathology in familial AD 
ArcticAβ mice. Already at the pre-plaque stage, these mice were highly sensitive to KA and 
required application of diazepam after surgery to prevent immediate mortality. Nevertheless the 
majority of KA-treated ArcticAβ mice died during the following months after injection. A group 
of mice that survived till 9 months had a “mild” KA lesion phenotype, with degeneration only in 
the CA1 region. Unexpectedly, the ipsilateral hippocampus was devoid of Aβ plaques. As there 
was no difference in plaque load in the neocortex of these mice compared to control, we 
concluded that KA injection induces changes that prevent or delay plaque formation.  
Suppression of adult neurogenesis was shown to enhance the effects of KA. Many FAD mice are 
reported to have altered adult neurogenesis. We attempted to explain the sensitivity of ArcticAβ 
to KA by characterizing adult neurogenesis in the hippocampus. Immature adult born neurons 
showed decreased dendritic arborization and decreased spine density. Impaired maturation of 
adult-born neurons can result in their inadequate integration within the hippocampal networks. It 
is known that adult-born neurons exert net inhibitory effect on dentate gyrus-CA3 network in the 
hippocampus; therefore, this could contribute to the sensitivity of ArcticAβ mice to KA.  
Dysfunction of interneurons is frequently reported in AD. GABAergic interneurons orchestrate 
network oscillatory activity or/and control firing rate and patterns of principal cells. The second 
major part of this thesis focused on a unique newly described inhibitory strengthening 
mechanism in cerebellar stellate interneurons. It has been shown that an increase of 
mitochondrial reactive oxygen species (mROS), for example due to high metabolic demand in 
the cell, can function as a protective feedback mechanism by recruiting more GABAARs to the 
synapses. Interestingly, the recruited receptors have distinct subunit composition and decay 
kinetics in comparison to the resident predominant receptors.  Here, we show that repeated high 
XIII 
frequency stimulation of the input fibers leads to un-silencing of a distinct pool of GABAARs by 
recruiting them to the synapse. The exact mechanisms and signaling pathways that underlie this 
strengthening of GABAergic transmission are still to be uncovered. However, the breakdown of 
such a protective internal feedback mechanism could trigger abnormal firing of interneurons, or 
even their degeneration due to oxidative stress. This, in turn, would have a major impact on 
entire networks. If proved to be a common mechanism in many other types of interneurons, 
failed un-silencing of GABAergic synapses by mROS might contribute to the pathophysiology 
of many CNS disorder, including AD. 
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I. GENERAL INTRODUCTION 
Alzheimer’s disease (AD) 
First described at a conference over a century ago in Tübingen, Germany, by the psychiatrist and 
neuropathologist Alois Alzheimer, Alzheimer’s disease (AD) is now recognized as the most 
common age-related dementia affecting millions of people world-wide (Ferri et al., 2005, Prince 
et al., 2013). Typically, memory deficits are the first cognitive symptoms of developing AD. 
With progression of the disease an array of cognitive abilities gradually declines and patients can 
exhibit problems with spatial orientation, troubles with executing daily tasks, such as handling 
money or getting dressed. At later stages memory continues to deteriorate. Patients have 
problems communicating and recognizing family and friends have changes in personality and 
behavior may experience hallucinations, delusions, and many are reported to have seizures. At 
latest AD stages, patients have other physiological symptoms, such as difficulties controlling 
bowel and bladder, difficulties swallowing, increased sleeping, weight loss. (National Institute of 
Ageing, NIH, 2017, https://www.nia.nih.gov/alzheimers/topics/symptoms) Post-mortem brain 
tissue of AD patients is characterized by severe neurodegeneration, extracellular accumulation of 
amyloid-β (Aβ) peptide plaques, intracellular formation of neurofibrillary tangles (NFTs), that 
consist of hyperphosphorylated tau protein and neuroinflammation (Castellani et al., 2010, 
Serrano-Pozo et al., 2011). 
APP processing and amyloid cascade hypothesis 
Most AD cases are sporadic and about 1% of AD cases are familial, with an identified 
underlying genetic cause and those are mostly early-onset. About two hundred autosomal 
dominant mutations in amyloid precursor protein (APP) and presenilin 1 and 2 genes (PS1 and 
PS2), which contribute to proteolytic cleavage of Aβ, are associated with early-onset familial 
forms of AD (Cruts et al., 2012); Alzheimer Disease and Frontotemporal Dementia Mutation 
Database http://www.molgen.vib-ua.be/ADMutations). The gene encoding APP belongs to the 
class of housekeeping genes (Salbaum et al., 1988, Izumi et al., 1992, Quitschke and Goldgaber, 
1992). Although the functions of APP are still being investigated, it was shown to play a role in 
development of CNS, neurite outgrowth and synaptogenesis (Muller et al., 2017).  Neurons 
produce large amounts of APP, which is cleaved by α, β and γ-secretases enzyme complexes. In 
the non-amyloidogenic pathway, cleavage of APP by α-secretase occurs within the Aβ domain 
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and consequently prohibits Aβ peptide production. APP is cleaved by α-secretase (ADAM9, 
ADAM10 and ADAM17) to generate two fragments; a transmembrane 83 amino acid C-terminal 
fragment (C83) and an N-terminal ectodomain (sAPPα) that is released into the extracellular 
space (Figure 1) (Allinson et al., 2003). sAPPα can be further cleaved by γ-secretase into 
fragments that are thought to be irrelevant for the progression of the disease. On the other hand, 
the amyloidogenic pathway leads to generation of neurotoxic Aβ species. The first proteolysis 
step is mediated by β-secretase (BACE1), which releases a large N-terminal ectodomain (sAPPβ) 
into the extracellular space and leaves a 99-amino acid C terminal fragment (C99) remaining in 
the membrane (Sinha et al., 1999, Sinha and Lieberburg, 1999, Vassar et al., 1999). Aβ is 
released when C99 is further cleaved by γ-secretase between residues 38 and 43.                                                                                                                                                                                 
γ-secretase is a complex of enzymes consisting of presenilin 1 or 2 (PS1 and PS2), nicastrin, 
anterior pharynx defective (APH-1) and presenilin enhancer 2 (PEN2) (Wolfe et al., 1999, Yu et 
al., 2000, Levitan et al., 2001, Francis et al., 2002, Steiner et al., 2002). 
Aβ peptide is highly resistant to proteolytic degradation. Aβ isoforms consist of 37-43 amino 
acids, among which Aβ1-40 and Aβ1-42 are the most common. Prone to β-sheet type folding, 
hydrophobic Aβ1-42 is the most toxic isoform, that predominantly forms the core of the amyloid 
plaques. Location of familial mutations within APP and APP processing machinery genes and 
Aβ1-42 toxicity lead to the emergence of amyloid cascade hypothesis (Hardy and Higgins, 1992). 
The hypothesis centers around the generation of toxic Aβ species being a major cause of the 
disease.  
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Figure 1. APP processing. Amyloid precursor protein (APP) is cleaved by multiple secretases. In non-
amyloidogenic pathway Aβ region of APP is cleaved in the middle by α-secretase and two soluble APP 
fragments are released. The amyloidogenic pathway results in releases of Aβ peptides after APP has been 
cleaved by β- and γ-secretases (Van Dam and De Deyn, 2006). 
Cholinergic hypothesis 
The cholinergic system in the brain is involved in neuromodulation and some deterministic tasks 
that affect learning and memory (Picciotto et al., 2012, Sarter et al., 2014). The “cholinergic 
hypothesis” was the first approach to describe AD pathophysiology.  It was defined in the 70s 
after correlating mental state of the patients with post-mortem histopathological and biochemical 
alterations. These screenings identified selective damage to cholinergic neurons and axons in the 
hippocampus, frontal cortex, amygdala, nucleus basalis and medial septum, regions involved in 
learning and memory, conscious awareness, and attention. Findings included decreased activity 
of choline acetyltransferase (ChAT) (Bowen et al., 1976, Davies and Maloney, 1976, Perry et al., 
1977), reduced choline uptake (Rylett et al., 1983), decrease in ACh release (Nilsson et al., 
1986), reduced levels of nicotinic and muscarinic M2 receptors (Whitehouse et al., 1988, 
Nordberg et al., 1992a), at presynaptic terminals and degeneration of ACh producing cells in the 
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basal forebrain and medial septum (Whitehouse et al., 1982, Francis et al., 1999). Postsynaptic 
muscarinic receptors appeared to be less affected (Whitehouse et al., 1988, Nordberg et al., 
1992b),.  
Alterations in cholinergic system have been associated with development of histopathological 
hallmarks of AD. For instance, the non-selective muscarinic antagonist scolopamine can induce 
cognitive impairment and decrease the activity of α-secretase, leading to increased production of 
Aβ peptide (Liskowsky and Schliebs, 2006). As for tau pathology, in vitro studies have linked 
activation of M1 muscarinic receptors to decreased Tau phosphorylation (Sadot et al., 1996). 
Muscarinic M1 receptors were shown to affect the level of activated major Tau kinase - GSK-3β 
(Medeiros et al., 2011). 
Major AD therapy drugs are competitive inhibitors of ACh esterase – the enzyme that breaks 
down ACh. These drugs promote temporary cognitive improvement, but are not effective in all 
patients (Francis et al., 1999, Cummings et al., 2014), which raises questions about the causal 
role of cholinergic system defects in development of sporadic AD (Craig et al., 2011).  
Role of long-range brainstem projections in AD 
It has been observed that AD-related pathology first appears at specific sites in the human brain 
and further spreads to other regions in a specific manner (Braak and Braak, 1991, Nelson, 2007, 
Duyckaerts et al., 2009a, Duyckaerts et al., 2009b, Nelson et al., 2011, Serrano-Pozo et al., 2011, 
Hyman et al., 2012, Montine et al., 2012). The first observable AD-related alteration is 
hyperphosphorylation and aggregation of cytoskeletal protein tau. This pathology can first be 
seen in the brainstem nuclei that project to the cerebral cortex. Serotonergic upper raphe nuclei, 
the noradrenergic locus coeruleus and cholinergic magnocellular nuclei are among them.  Those 
nuclei contain neurons with longest axons in the CNS that are prone to increased mitochondrial 
oxidative stress during aging (Sanchez-Padilla et al., 2014). Oxidative stress can directly induce 
tau aggregation (Schweers et al., 1995), which can lead to formation of PHFs as well as early 
NFT-induced neurodegeneration (Grudzien et al., 2007). The density of Aβ plaques is high in the 
projection areas of these brainstem nuclei, such as the olfactory bulb, striatum, neocortex, 
cerebellar cortex, tectum and lower brainstem and minimal in brainstem nuclei. It was suggested 
that Aβ is released from the non-junctional varicosities of long range axons of brainstem neurons 
with tau pathology (Braak and Del Tredici, 2013). 
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Synaptic dysfunction in AD 
It was recognized already over two decades ago, that severity of AD related cognitive 
impairments correlates with the degree of synaptic loss rather than with Aβ plaque load or 
neurofibrillary tangles (Hamos et al., 1989, DeKosky and Scheff, 1990, Robinson et al., 2014). 
Synaptic dysfunction occurs before plaque pathology (Oddo et al., 2003). Almost 30% decrease 
of cortical synapses and a reduction in pre-and postsynapse-associated proteins was reported in 
patients with AD (Reddy and Beal, 2008). Soluble Aβ monomers can form low molecular weight 
(LMW) oligomers (dimers or trimers), or high molecular weight (HMW) oligomers and fibrils or 
protofibrils, that deposit in plaques (Larson and Lesne, 2012). Notably, Aβ oligomers but not 
fibrils have been associated with synaptic alterations (Ferreira and Klein, 2011). High 
concentrations of soluble Aβ oligomers are found in cerebrospinal fluid (CSF) of AD patients. 
Soluble Aβ oligomers were found associated with synapses in the vicinity of Aβ plaques in 
brains of AD patients, but not in asymptomatic controls (Herskovits et al., 2013, Bilousova et al., 
2016).  Soluble oligomers contribute to cognitive impairments in AD patients by inhibiting long-
term potentiation (LTP) and facilitating long-term depression (LTD) at excitatory synapses. 
There is evidence indicating that specifically LMW oligomers contribute to synaptic loss, which 
ultimately leads to permanent memory loss. HMW oligomers appear to be less toxic, but were 
shown to be capable of dissociating into LMW oligomers (Wang et al., 2016, Yang et al., 2017),  
Already before the occurrence of classical AD pathological hallmarks, accumulation of Aβ is 
observed intracellularly and shown to be toxic (Wirths et al., 2012, Youmans et al., 2012, Iulita 
et al., 2014, Yang et al., 2017). Concentration of HMW and LMW oligomers increases in brain 
interstitial fluid with age. Evidently, at later stages Aβ oligomers can derive from plaque halo 
and accumulate at excitatory synapses at both pre- and postsynaptic sites (Heras-Sandoval et al., 
2012, Takeda et al., 2013, Pickett et al., 2016). It is suggested that Aβ oligomers exert their toxic 
effect by binding to postsynaptic receptors (Um et al., 2013, Jarosz-Griffiths et al., 2016). Aβ 
oligomers can bind to both ionotropic and metabotropic receptors. Through the recruitment of 
Nedd4-1ubiquitin ligaze, Aβ oligomers induce reduction of surface AMPA receptors, spine 
density and synaptic strength. Aβ oligomers were also shown to be able to induce LTD through 
NMDA receptors and PKCα/PICK1 (protein kinase C α/ protein interacting with C kinase 1) 
dependent pathways that lead to the reduction of AMPA receptors in the synapses (Alfonso et 
al., 2014, Alfonso et al., 2016, Reinders et al., 2016, Rodrigues et al., 2016). 
In conclusion, in the recent decade a progress in accepting a crucial role of oligomers in AD 
pathophysiology has been made. With advance in PET imaging it is now possible to measure 
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synaptic density in human patients which would contribute to both early diagnosis and research 
in the field (Finnema et al., 2016). Reducing the presence or availability of Aβ oligomers is a 
promising therapeutic goal. 
Familial AD mouse models 
Overexpressing mutant human APP is the most common strategy to generate AD transgenic 
mouse models. The Aβ sequence of wildtype mice and humans differ and due to the fact that 
mice do not develop AD, transgenic mouse lines have to be used (Dyrks et al., 1993). Mice that 
overexpress wild-type human APP have only mild neuropathological changes without deposition 
of Aβ plaques, suggesting that wildtype APP overexpression alone may not trigger the human 
disease efficiently in mice (Buxbaum et al., 1993, Lamb et al., 1999, Mucke et al., 2000). On the 
other hand, expression of human APP or presenilin with FAD mutations leads to age-dependent 
development and maturation of Aβ plaques in the brain (Platt et al., 2013). The age of the onset 
of Aβ plaques deposition varies between mouse models, depending on specific mutations. In 
FAD mouse models plaques usually start to form after the age of 6-7 months. There are some 
exceptions, for instance 5xFAD mouse model, which combines 5 mutations in APP and 
presenelin and develops extensive plaque pathology by 2 months of age (Oakley et al., 2006). 
Cognitive impairments are also present in many transgenic mice (Games et al., 1995, Hsiao et 
al., 1996, Sturchler-Pierrat et al., 1997). Such hallmarks as synaptic loss, dystrophic neurites, 
reactive astrocytes and activated microglia usually follow and accompany the formation of Aβ 
plaques.  
In our study we used ArcticAβ transgenic FAD mouse line that expresses human APP695 with 
Swedish (Swe; KM670/671NL) and Arctic (E693G) mutations under the prion protein promoter 
(PrP) (Knobloch et al., 2007).  Swedish mutation is a double mutation, the only one known, that 
is immediately adjacent to the β-secretase site in APP. This mutation runs in two large Swedish 
families which were found to be genealogically connected (Mullan, 1992, Mullan et al., 1992). 
In vitro studies showed that this mutation increases the production and secretion of Aβ40 and 
Aβ42, without affecting the Aβ40/Aβ42 ratio. (Citron et al., 1992, Cai et al., 1993, Citron et al., 
1994, Johnston et al., 1994, Citron et al., 1996, Scheuner et al., 1996, Nilsberth et al., 2001). The 
Arctic mutation found in a family from Northern Sweden is one of a few mutations located in Aβ 
sequence of APP. The biological effect of the Arctic mutation comprises an increased propensity 
and faster rate Aβ40 protofibrils formation in comparison to wild-type Aβ40 (Nilsberth et al., 
2001). Along with other mutations found in Aβ sequence, the Arctic mutation causes cerebral 
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amyloid angiopathy (CAA), probably due to inefficient clearance of Aβ across the blood-brain 
barrier (BBB) (Monro et al., 2002, Lashuel et al., 2003).  
ArcticAβ mice show increased Aβ production, which is followed by the formation of 
intracellular punctate Aβ deposits that coincide with onset of behavioral deficits. Impaired 
working memory in ArcticAβ mice was first observed at the age of 6 months, preceding the 
formation of extracellular Aβ plaques and the development of CAA. This finding suggests an 
important role of early Aβ deposits in the pathogenesis of AD. 
Sporadic AD mouse model 
Familial AD (FAD) mutations are responsible for early-onset relatively rare cases of AD. Most 
AD cases occur sporadically and later in life (Herrup, 2010). Interestingly, genome wide 
association studies did not identify a correlation between polymorphisms in genes encoding APP 
and APP processing enzymes and the incidence of late-onset AD.  Except a well-known risk 
factor for AD - Apolipoprotein E ε4 allele (APOE4) (Corder et al., 1993), genome-wide 
association studies have shown correlation between polymorphisms in genes of the innate 
immune system and late-onset disease incidence. (Harold et al., 2009, Lambert et al., 2009). 
Therefore, the underlying pathogenesis could differ between the familial and sporadic forms of 
AD.  
Animal models used in AD research are based on FAD mutations, and considering the 
epidemiology of AD, the field would immensely benefit from reliable models of sporadic AD.   
Large amount of evidence link immune system function to AD. The exact role is still debated. 
Activation of innate immunity was implicated in triggering AD, being beneficial, or considered 
to be a disease by-product (Wyss-Coray, 2006).  For instance, it was shown that exogenously 
applied interleukin (IL) 1 increases APP levels and Aβ peptides production in vitro (Sheng et al., 
1996). Tumor necrosis factor alpha (TNFα) has also been shown to increase Aβ peptides 
production in vitro and in vivo (Li et al., 2004, Medeiros et al., 2007, Yamamoto et al., 2007). 
Elevation of TNF receptors in humans has been associated with increased β-secretase activity 
and increase levels of Aβ in CSF, which is a predictor of mild cognitive impairment (MCI) 
patients developing into AD (Buchhave et al., 2010). Interestingly, people who suffer from 
rheumatoid arthritis and take non-steroidal anti-inflammatory drugs (NSAIDs) have lower risk of 
developing AD (McGeer and McGeer, 1996, McGeer et al., 1996, Stewart et al., 1997). These 
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are just some examples of the numerous findings that implicate the immune system in the 
development of AD pathology.  
 
Figure 2: “Double-hit” mouse model for sporadic AD. Pregnant dams (GD17) were i.v. injected with 5 
mg/kg of PolyI:C  at gestational day 17 (GD17). First generation (F1) offsprings  exposed only to prenatal 
PolyI:C (“single hit”) develop AD-related changes with age, including central increased levels of pro-
inflammatory cytokines (IL-1a and -1b and IL-6), activation of microglia and increased levels of APP and 
pTau. A second exposure of F1 to PolyI:C (5 mg/kg) at the age of 12 months (“double hit”) exacerbates 
the phenotype detected at the age of 15 months, resulting in more prominent micro- and astrogliosis, 
further APP elevation and formation of APP-positive plaques as well as increased formation of paired 
helical filaments (PHFs) and a somatodendritic shift of pTau. Illustrations taken from 
http://smart.servier.com/. 
 
The immunostimulant polyinosinic:polycytidylic acid (PolyI:C), which mimics viral infections 
by interacting with toll-like receptor 3 (TLR3), expressed by B-cells, macrophages and dendritic 
cells, is widely used in immune research. Structurally it resembles double-stranded RNA, present 
in some viruses. It was previously shown that systemic administration PolyI:C to pregnant mice 
during late gestation causes a long-lasting elevation of inflammatory cytokines, memory 
impairments and accelerated deposition of aggregated proteins in the offspring (Meyer et al., 
2006, Meyer et al., 2008, Knuesel et al., 2009).  Exposure of the offspring to a second PolyI:C 
challenge in adulthood triggered development of AD-like pathology during ageing (Krstic et al., 
2012). The same systemic immune challenge in adult transgenic AD mice also exacerbated age-
related AD-like pathology, suggesting a causal role of chronic activation of the immune system 
in this process.  
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Comorbidity of AD and epilepsy 
AD and epilepsy are largely viewed as separate syndromes belonging to distinct medical 
subspecialities. In the recent years, there has been mounting evidence for comorbidity of these 
two diseases. For instance, patients suffering from AD have 6 to 10- fold higher risks to develop 
seizures and epilepsy compared to the healthy individuals of the same age (Hesdorffer et al., 
1996a, Amatniek et al., 2006, Scarmeas et al., 2009). Interestingly, epileptic activity in some 
cases was shown to occur at the early “pre-degenerative” disease stages in AD patients and is 
associated with cases of more severe dementia (Hesdorffer et al., 1996b, Mendez and Lim, 2003, 
Amatniek et al., 2006, Scarmeas et al., 2009, Noebels, 2011). Moreover, seizures are suggested 
to contribute to the progression of AD (Vossel et al., 2013). Interestingly, even in people with 
identified genetic risks of developing AD, neurological examination performed decades before 
the symptoms might occur reveal activity disturbances in specific networks during memory-
related tasks (Mondadori et al., 2006, Bateman et al., 2012, Reiman et al., 2012) From the side of 
epilepsy research, some epilepsy patients often have recurrent memory disturbances that closely 
resemble clinical features of early stages of AD (Jokeit and Ebner, 1999, Sinforiani et al., 2003, 
Lozsadi et al., 2008, Ito et al., 2009a). In addition, epileptic patients have increased incidence of 
senile plaques (Mackenzie and Miller, 1994, Gouras et al., 1997). This observation suggests that 
both epileptogenesis and early development of AD pathology might have common 
pathophysiology and that recurrent seizures might aggravate AD pathology and vice-versa.  
Seizures in AD mouse models 
For logistics and ethics reasons invasive EEG monitoring in human patients is not always 
feasible. This is one of the reasons for the absence of systemic large scale studies describing the 
incidence of seizures in human AD patients. More systemic, lengthy and invasive monitoring is 
possible to perform in animal models. A number of FAD transgenic mice that express human 
mutant APP show seizures prior the development of AD pathology hallmarks, such as 
Aβ plaques (Palop et al., 2007, Chin, 2008). Alterations on synaptic and molecular level can 
affect overall network function, which in turn, closing the vicious circle, can affect individual 
synapses and molecules. For instance, hAPPJ20 line, that combines Swedish double and Indiana 
mutations, has epileptiform activity such as spikes and sharp waves. Spontaneous epileptiform 
discharges occur in hAPPJ20 mice during reduced gamma oscillatory activity (20-80Hz), which 
is abnormal in this mouse line due to impairments in interneurons that underlie the generation of 
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this rhythm (Verret et al., 2012a). Overexcitability in the network may increase Aβ production. 
Excessive Aβ peptide production affects synaptic plasticity that may lead to cognitive deficits.  
It was suggested that seizures could contribute to the cognitive deficits that occur prior amyloid 
deposition. Those deficits comprise impairments in spatial memory and anxiety (Palop et al., 
2003, Palop et al., 2007). Interestingly, inhibiting seizures reduces these deficits (Roberson et al., 
2011, Sanchez et al., 2012). Early seizure offset in transgenic AD mice suggests the importance 
of oligomeric Aβ species in their development. When seizures become evident, the absence of 
extensive neuronal loss in the AD mouse models underscores that in this case neurodegeneration 
is not a prerequisite for epilepsy in this disorder. In addition, hAPP mice have circuit 
reorganization typically induced by epileptiform activity. This includes upregulation of 
neuropeptide Y in GABAergic interneurons and the hippocampal mossy fiber pathway (Palop et 
al., 2007, Roberson et al., 2007).  
 
 
Epileptic activity and network disturbances are frequently seen in FAD mouse models. The 
occurrence of those abnormalities prior the development of plaque pathology suggests a possible 
crucial role of epileptic-like activity in the development of AD pathology.   
Temporal lobe epilepsy and kainic acid mouse model 
Unilateral intrahippocampal injection of KA in adult mice causes a local lesion with progressive 
neurodegeneration of CA1 pyramidal cells and hilar cells, granule cells dispersion, severe 
astrogliosis and persistent microglial activation in the affected hippocampus. Life-long non-
convulsive focal spontaneous recurrent seizures (SRS) appear after a two-week long latent phase 
(Bouilleret et al., 2000, Riban et al., 2002, Arabadzisz et al., 2005, Duveau et al., 2011b). Like in 
human TLE patients, SRS in mice rarely generalize and tend to remain focal. Seizures in AD are 
rarely detected with cortical EEGs (Noebels, 2011), making the KA mouse model optimal for 
investigating the link between AD and epilepsy.   
Focal inflammatory processes commonly occur in TLE and other epilepsies. Among them are 
enhanced production of IL-1β and other cytokines by glial cells. This promotes neuronal 
hyperexcitability and neurodegeneration through the activation of a number of signaling 
cascades via TLRs (Friedman and Dingledine, 2011, Vezzani et al., 2011a, Vezzani et al., 
2011b). Focal seizures cause local inflammation that promotes infiltration of brain parenchyma 
by macrophages and lymphocytes from periphery. Prevention of this infiltration reduces SRS in 
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mice (Fabene et al., 2008). PolyI:C or lipopolysaccharide (LPS) (bacterial toxin) challenge 
during development was shown to influence mouse susceptibility to epileptogenic substances in 
adulthood, initially acting through TLRs. Inflammation, as an undeniable companion of many 
epilepsies could represent a link through which abnormal neuronal excitability could influence 
AD-like pathology.  
Neurogenesis in AD and epilepsy 
The birth of neurons after the initial early development continues in adult brain in specific 
niches, namely subgranular zone (SGZ) of the hippocampal dentate gyrus (DG) and the 
subventricular zone (SZ) (Kempermann et al., 2015). During human life around 35% of the DG 
neurons are replaced, which is more than three times more than in rodents (Ninkovic and Gotz, 
2007, Imayoshi et al., 2008). Adult hippocampal neurogenesis plays a role in synaptic plasticity, 
learning and memory, and pattern separation. Cognitive deficits in AD may be, at least partly, 
due to impairments in adult neurogenesis (Demars et al., 2010, Lazarov and Marr, 2010, Lazarov 
et al., 2010, Demars et al., 2013). 
Adult neurogenesis seems to be almost always affected in one way or another in AD in both 
humans and rodents. There are conflicting results among studies analyzing neurogenesis in AD 
patients, showing depletion or increase (Nagy et al., 1997, Boekhoorn et al., 2006, Ziabreva et 
al., 2006). Analysis of neurogenesis in different FAD mouse models varies from line to line, but 
in many cases neurogenesis is negatively affected (Wang et al., 2004 (Wang et al., 2004, 
Donovan et al., 2006, Taniuchi et al., 2007, Zhang et al., 2007, Rodriguez et al., 2008). Some 
animal models show increased proliferation, but decreased survival of the newborn neurons 
(Chevallier et al., 2005, Yu et al., 2009). Neurogenesis in hAPPJ20 mice is characterized by 
accelerated early development, but impaired maturation of adult-born granule cells. This was 
linked to increased GABAergic input to these cells and to further synaptic rewiring (Sun et al., 
2009). A number of other studies linked AD-related disturbances of GABA-mediated inhibition 
to changes in adult neurogenesis. (Ge et al., 2007, Song et al., 2012, Wang et al., 2014). 
Recent studies  revealed a role  adult  neurogenesis  plays in  seizure  susceptibility  in  multiple 
epileptic  mouse  models.  Suppression of neurogenesis can increase the acute  effect  of  KA in 
mice (Iyengar et al., 2015). Adult-born neurons have a net inhibitory effect on the DG-CA3 
network (Acsady et al., 1998). ArcticAβ mice that share hAPP Swedish mutation with hAPPJ20 
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are likely to have disturbances in adult neurogenesis. Depending on the alteration, this at least 
partially, could explain sensitivity of these animals to KA.   
Mechanisms of GABAergic synaptic strengthening 
Glutamate and γ-Aminobutyric acid (GABA) mediate excitatory and inhibitory 
neurotransmission, respectively. Glutamate is converted into GABA by glutamic acid 
decarboxylase (GAD), which is located at GABAergic axon terminals. Vesicular glutamate 
transporter (VGluT) and vesicular GABA transporter (VGAT) are required for packing of 
respectively glutamate or GABA into synaptic vesicles, for further exocytosis and 
neurotransmission. At the postsynapse glutamate activates ionotropic α-amino-3-hydroxy-5-
methyl-4-isoxazolepropionic acid (AMPA) and kainite receptors, that mediate fast excitatory 
transmission and N-methyl-D-aspartate (NMDA) receptors that have slower kinetics and play a 
central role in the synaptic plasticity (Luscher and Malenka, 2012). Glutamate also activates G-
protein coupled metabotropic glutamate receptors (mGluRs) that also play a role in synaptic 
plasticity at both post- and presynapse. 
At the postsynaptic membrane, GABA activates GABAA and GABAB receptors. GABAB are 
metabotropic inhibitory receptors that are G-protein coupled to potassium channels. Upon 
activation they “bring” neuron closer to the equilibrium potential of K+, thus inhibiting action 
potential firing (Pin and Bettler, 2016). GABAARs are Cys-loop ligand-gated chloride ion 
channels that mediate most of fast inhibitory transmission in the brain. GABAARs form 
pentameric assemblies. So far 19 genes encoding different GABAARs subunits in mammals have 
been identified (α1–α6, β1–β3, γ1–γ3, δ, ε, π, τ, ρ1–ρ3) (Olsen and Sieghart, 2009). Most 
frequent GABAA receptor subunit arrangement in the CNS is 2α/2β/γ. Many distinct 
combinations of GABAA receptors exist throughout the brain and they differ in their kinetics, 
pharmacological properties and expression distributions (Fritschy and Panzanelli, 2014). 
Postsynaptic or extrasynaptic localization of GABAA receptors determines the form of inhibition 
they mediate. Postsynaptic receptors usually contain α1, α2 or α3 along with β variants and γ2 
and mediate fast, phasic currents upon presynaptic GABA release; extrasynaptic receptors 
usually contain α4, α5 or α6, two of the β2 subunits and δ subunit and mediate tonic (persistent) 
inhibition by ambient GABA. This consistent pattern suggests that subcellular targeting of 
GABAARs can be subunit specific (Belelli et al., 2009, Brickley and Mody, 2012). Strength of 
GABAergic transmission is modulated by the network activity. Both post- and extrasynaptic 
receptors are regulated by posttranslational mechanisms through influencing receptor biophysical 
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properties, trafficking and synaptic confinement. (Luscher et al., 2011, Connelly et al., 2013). 
Scaffolding proteins such as gephyrin play a major role in postsynaptic targeting of GABAARs. 
Gephyrin interacts with many proteins and thus contains numerous phosphorylation and 
posttranslational modification sites, providing a hub for regulation of postsynaptic GABAARs by 
various factors (Fritschy et al., 2008) (Tyagarajan and Fritschy, 2014). GABAAR-associated 
protein (GABARAP) is another regulator of GABAARs mobility. GABARAP is involved in 
exocytosis of GABAARs as a result of potentiation of glutamatergic synapses  (Marsden, 2007). 
There are many open questions about the exact action of GABARAP, since multiple isoforms of 
it exist. GABARAP-KO mice show normally clustered GABAARs. (O'Sullivan et al., 2005). It 
was suggested that GABARAP is not solely regulating GABAAR trafficking, but forms 
complexes with other proteins to exert its function (Mizokami et al., 2007). 
Dysregulation of mechanisms underlying the balance between neuronal excitation and inhibition 
and activity-dependent synaptic strengthening could be crucial in pathogenesis of a wide array of 
neurological diseases including epilepsy and AD. 
Neuronal excitation and energy metabolism are tightly linked. The generation of mROS at the 
electron transport chain in the inner mitochondrial membrane can be viewed as a reflection of the 
intensity of cellular metabolism.  Although mROS overproduction and accumulation leads to 
oxidative stress and is damaging for the cells, lower concentrations of mROS can be beneficial. 
For instance, mROS can be viewed as a signaling molecule involved in adaptations to hypoxia, 
regulation of autophagy, cell differentiation and aging (Sena and Chandel, 2012). 
Cerebellar stellate cells are a subtype of GABAergic interneurons in the cerebellar molecular 
layer that innervate Purkinje cells dendrites. Stellate cells receive stable inhibitory transmission, 
which makes them an ideal cell type for obtaining reliable intracellular recordings of high 
amplitude, high frequency GABAergic synaptic events. In young adult cerebellum, stellate cells 
GABAergic synapses contain GABAA receptors assembled mainly with α1, β2 and γ2 subunit 
variants. Pharmacological inhibition of ATP production in the mitochondria to increase mROS 
was shown to selectively increase the frequency of miniature IPSCs of smaller amplitude and 
slower decay kinetics in comparison to control conditions, as seen in whole cell patch clamp 
recordings. Interestingly, slow decay kinetics of newly occurring inhibitory postsynaptic events 
matched kinetic properties of GABAA receptors containing the α3 subunit, which are expressed 
at low levels in stellate cells. The mROS-dependent recruitment of these receptors was 
demonstrated by using α3 subunit knock-out mice. Therefore, this data unravelled the existence 
of a molecular pathways triggered by mROS that selectively recruit extrasynaptic receptors to 
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postsynaptic sites in order to strengthen GABAergic transmission. This is the first study to link 
mROS to signaling the metabolic state of the cell to GABAergic transmission (Accardi, 2014). 
Furthermore, in cerebellar granule cells, extracellular insulin application was shown to 
strengthen inhibitory synapses by elevating mROS, leading to recruitment of α6 subunit-
containing GABAARs (Accardi et al., 2015), suggesting that this mechanism, involving 
GABAARs that do not reside in postsynaptic densities might be universal. 
Interneurons are important regulators of network rhythmicity and excitability of principal 
neurons. Impairments in interneuron firing or synaptic function and plasticity could underlie 
changes in synchrony and excitability of networks. mROS induced plasticity was already 
observed in two cell types in the cerebellum. It still remains to be researched if this plasticity is a 
universal way for many other neuronal types Dysfunction of mROS-induced strengthening could 
lead to network abnormalities and excessive oxidative stress, which could affect neuronal 
survival. mROS induced plasticity  related pathways could be a promising candidates for search 
of novel therapeutic targets.   
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II. AIM OF THE THESIS 
The central objective of this thesis is to contribute to the understanding of the neurodegenerative 
disorders by exploring a wide scope of mechanisms that could underlie them. On the network 
scale my thesis is focused on how epileptic activity contributes to Alzheimer’s disease 
pathology. On a synaptic scale this work further investigates recently described inhibitory 
plasticity mechanisms, which are regulated by activity and metabolic state of a neuron. A 
breakdown of this plasticity mechanism can lead to increased network excitability which may in 
turn contribute to the development of a neurodegenerative disorder. 
Study I.  Effects of acquired seizures on AD pathology in sporadic and familial mouse 
models 
In this project we investigate the role of epileptic activity in the development  of  AD  by  
inducing  epileptic-like  pathology  in  mice  predisposed  to  AD.  To do this, we combine 
intrahippocampal kainic acid  (KA)  injection -  a model widely used to mimic TLE with AD 
mouse models. 
Sporadic AD  
 Can induction of seizures in AD-susceptible brain trigger AD pathology reminiscent of 
the one induced by the second PolyI:C hit? 
 Are chronic seizures a predisposition for developing AD-like pathology after a PolyI:C-
induced immune challenge?  
To address these questions pregnant WT  dams  were injected with  PolyI:C  at gestational  day  
17  (GD17).  The  offsprings  were  taken  into  experiments  at  the  age  of  3 months and were  
injected  intrahippocampally  with  KA. To answer the second question  WT  mice  were  
injected  with  KA at  3  months  of  age  and  1 month later they were intravenously injected 
with Poly:C. In both cases at the age of 9  and 15 months their brain tissue was collected and 
immunohistochemically analyzed for AD and neuroinflammation markers. 
Familial AD  
 How does epileptic activity induced at early stages of AD affect the development of 
known AD pathological hallmarks?  
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To answer this, FAD ArcticAβ mice were injected with KA when they were 3 months old. Their 
AD pathology was immunohistochemically analyzed 6 months after the KA treatment. 
Study II. Neurogenesis in ArcticAβ mice 
The results of the former project showed that ArcticAβ mice are highly sensitive to KA. We 
wanted to explore possible mechanisms that underlie this hypersensitivity. Taking into account 
recent research, we hypothesized that adult neurogenesis could be a contributing factor.  
 Is mutant hAPP overexpression or early increase in toxic intracellular Aβ species 
affecting adult neurogenesis in ArcticAβ mice? 
We used BrdU labeling to estimate proliferation and survival rates of progenitor cells and viral 
labeling to visualize and analyse dendritic morphology of adult-born neurons.  
Study III. Mechanisms of inhibitory synaptic strengthening 
This project was done in collaboration with Derek Bowie’s lab at McGill University in Montreal, 
Canada. It is focused on basic physiological  mechanisms  of  synaptic  strengthening,  which  
could  potentially  be  implicated  in  the changes  in  excitability in  disease conditions 
Specifically, here, we are further investigating recently described mROS-induced GABAergic 
synaptic plasticity in a subpopulation of cerebellar interneurons (Accardi et al., 2014, Accardi et 
al., 2015). 
 Can repeated increased input activity trigger un-silencing of a population of GABAARs in 
the stellate interneurons?  
 Is this type of synaptic strengthening mROS-dependent?  
 Can this type of synaptic strengthening be induced by insulin? 
To address these questions we performed whole cell patch clamp recordings of stellate 
interneurons. To detect strengthening of GABAergic synapses, we used extracellular minimal 
stimulation of input fibers to the recorded neuron. To un-silence GABAARs we used repeated 
high frequency stimulation or bath application of insulin. 
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Abstract 
The vast majority of Alzheimer’s disease (AD) cases are sporadic and only about one percent are 
familial.  Since non-transgenic mice do not develop AD, it has been difficult to establish a mouse 
model of sporadic AD. Recently it was shown that prenatal inflammation induced by injecting 
pregnant dams with the viral mimic PolyI:C triggers long-term elevation of several cytokines and 
chemokines, which, coupled with a second immune challenge in adulthood, triggers symptoms 
of sporadic AD-like neuropathology with age. This “double hit” approach allows to model 
features of sporadic AD in wildtype mice. 
In the recent years it has become increasingly accepted that AD and epilepsy may overlap. 
Clinically and experimentally, abnormal epileptic activity can occur prior to the onset of AD 
plaque pathology. Therefore, research is needed to disentangle the pathophysiological 
mechanisms common to both syndromes.  
The aim of this study was to determine whether acquired seizures exacerbate AD-like pathology 
in sporadic and familial AD mouse models. We induced spontaneous recurrent seizures by 
unilateral intrahippocampal injection of kainic acid (KA) in wild-type sporadic “double hit” and 
transgenic ArcticAβ mouse models.   
The results of experiments with sporadic AD mice were negative; however, we did not observe 
the expected effects of PolyI:C treatment on brain microglia, preventing a definitive conclusion. 
On the other hand, ArcticAβ mice had strongly increased sensitivity to KA. Transgenic animals 
that aged till they were 9 months-old exhibited a mild KA lesion with degeneration and 
neuroinflammation exclusively present in the CA1 region. Surprisingly, aged KA-injected 
ArcticAβ mice were devoid of Aβ plaques in the ipsilateral hippocampus and had a reduced 
plaque load in the contralateral hippocampus when compared to wild-type littermates. This 
finding suggests that local changes induced at pre-plaque stage by KA, such as 
neuroinflammmation or neurodegeneration, or possibly chronic seizure activity, prevent or at 
least delay plaque formation. 
 
  
Introduction 
Alzheimer’s disease (AD) is one of the most prevalent age-related dementias. It is characterized 
by gradual loss of cognitive abilities, severe neurodegeneration and is associated with the 
formation of Aβ plaques and neurofibrillary tangles (NTFs) enriched with hyperphosphorylated 
tau.  
For several decades evidence has been accumulating suggesting that AD and epilepsy might 
share common pathophysiological mechanisms. For instance, patients suffering from AD have 6 
to 10 fold higher risk to develop seizures and epilepsy compared to healthy individuals of the 
same age (Sjogren et al., 1952, Hauser et al., 1986, Hesdorffer et al., 1996a, Amatniek et al., 
2006, Scarmeas et al., 2009). Epileptic activity in some cases was shown to occur at the early 
“pre-degenerative” disease stages in AD patients (Hesdorffer et al., 1996a, Mendez and Lim, 
2003, Amatniek et al., 2006, Scarmeas et al., 2009). On the other hand, epileptic patients have 
increased incidence of senile plaques (Mackenzie and Miller, 1994, Sheng et al., 1994, Gouras et 
al., 1997). Additional evidence came from AD mouse models, some of which have spontaneous 
seizures and neuropathological alterations reminiscent of those found in temporal lobe epilepsy 
(TLE) (Steinbach et al., 1998, Westmark et al., 2008, Palop and Mucke, 2010). TLE is a 
common type of epilepsy, which is characterized by severe neurodegeneration in hippocampal 
regions CA1 and hilus accompanied by reactive gliosis. Neuroinflammation (for instance, 
microglial activation, astrogliosis, elevation of inflammatory mediators) is a common feature in 
both AD and TLE.               
The majority of AD cases are sporadic and fewer than 1% are familial; however, the mouse 
models used in AD research are mostly transgenic lines overexpressing familial AD gene 
products. To determine the causes of sporadic AD, different mouse models would be highly 
valuable. Our lab previously showed that wild-type (WT) mice prenatally exposed to an immune 
challenge induced by a viral-mimic PolyI:C show long-term elevation of several immune 
mediators and a predisposition to develop AD-like pathology during aging. A second exposure 
of these mice to PolyI:C (or second hit) in adulthood leads to the formation of senile plaques, 
reminiscent of those in humans, and causes cognitive deficits (Krstic et al., 2012). This mouse 
model is potentially a good candidate to study the development of sporadic AD. 
The main goal of this project was to contribute to the understanding of the role of epileptic 
activity in the development of AD-like pathology by inducing chronic recurrent seizures in mice 
  
predisposed to this disease. We used intrahippocampal kainic acid (KA) injection - a model 
widely used to mimic TLE, combined with pre- and postnatal exposure to PolyI:C. Typical KA 
lesion is characterized by neurodegeneration in the hippocampal region CA1, loss of 
interneurons, dentate gyrus granule cell dispersion, severe local microgliosis and astrogliosis and 
establishment of spontaneous recurrent seizures (SRS) after a two week long latent period.  
The first part of the project focuses on the sporadic AD mouse model. Firstly, we wanted to 
determine whether in AD-susceptible brain, the induction of seizures could trigger AD pathology 
reminiscent of the one induced by the second PolyI:C hit (Group 1. prenatally PolyI:C treated 
mice). Next, we were interested whether epileptic activity together with an immune challenge in 
adulthood could induce AD-like pathology during ageing (Group 2. postnatally PolyI:C treated 
mice). 
The second part of the project focused on a familial AD mouse model, namely ArcticAβ mice. 
Those mice express human APP with two familial AD mutations, leading to an increase in toxic 
Aβ species and, starting at 7 months of age, Aβ plaques formation (Knobloch et al., 2007). With 
induction of seizures at pre-plaque stages in ArcticAβ mice we wanted to see whether this 
exacerbates the AD-like pathology that develops with ageing. 
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Materials and Methods 
Animals  
All experiments performed in this study were approved by the local authorities of the Cantonal 
Veterinary Office of Zurich and were carried out in accordance with Swiss Law on animal 
experimentation. 
Mice used in the experiments:  
- wild-type C57Bl6/JOla mouse strain (Harlan Laboratories, Horst, the Netherlands) 
- transgenic ArcticAβ (Knobloch et al., 2007), and their age-matched wild-type littermates 
(bred at the Laboratory Animal Sciences Center of the University of Zürich)  
All animals were housed in an in-house standard hygiene facility with access to food and water 
ad libitum under 12-hour light/dark cycle at the Institute of Pharmacology and Toxicology, 
University of Zurich, Switzerland. Both males and females were used in this study.  
Polyriboinosinic-Polyribocytidilic Acid (PolyI:C) injections 
Pregnant C57Bl/6JOla mouse strain dams were shipped on gestational day (GD) 14 and at GD17  
intravenously (i.v.) injected with PolyI:C (5mg/kg) potassium salt (P9582, 50 mg; Sigma-
Aldrich Chemie GmbH, Buchs, Switzerland) dissolved in 0.9% sterile NaCl. Injection volume of 
PolyI:C or saline was 5mL/kg body weight. During the injection procedure, the animals were 
restrained in acrylic mouse restrainer (PlasLabs, Inc. #561-RC). After the injection, dams were 
returned to their home cage. A group of offsprings for a part of the project was i.v. injected with 
PolyI:C or NaCl at the age of 3 months. 
Intrahippocampal kainic acid (KA) injection  
Two months old mice were anaesthetized with inhalation of 2.5-3% isoflurane (Baxter) in 
oxygen and received stereotactic injection of 70nL KA (5mM in NaCl; Tocris biosciences) or an 
equivalent volume of NaCl into the right dorsal hippocampus (stereotactic coordinates relative to 
Bregma: anteroposterior (AP) - 1.8mm, mediolateral (ML) -  1.6mm, dorsoventral (DV) -
1.9mm). Prior and after the surgery mice were intraperitoneally (i.p.) injected with 1mg/kg 
buprenorphine (Temgesic, Reckitt Benckiser AG, Switzerland). 
 
Tissue preparation for immunohistochemistry 
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Brain tissue of 9 or 15 months old animals was collected and treated according to the protocol 
described by Notter et al. (2014). Mice received an intraperitoneal injection of an anesthetic 
(Nembutal; 50mg/kg) and intracardially perfused with 15-20 mL at a flow rate of 10-15 mL/min 
by ice-cold, oxygenated aCSF (in mM: NaCl 125, KCl 2.5, CaCl2 3.7, MgCl2 2, NaHCO3 26, 
NaH2PO4 1.25, glucose 25). The brain was removed from the cranium and a block of brain tissue 
containing dorsal hippocampus was extracted. The block was immediately immersion fixed for 3 
hours in ice-cold fixative (4% paraformaldehyde in 0.15 M sodium phosphate buffer), pH 7.4. 
The block was rinsed with phosphate buffer saline (PBS) prior the cryoprotection in 30% sucrose 
in PBS overnight at 4 °C.  
Fixed tissue was cut into 40µm thick coronal sections using sliding microtome and collected in 
ice-cold PBS. For long term storage at -20 °C, sections were placed to a cryoprotectant solution 
(50 mM sodium phosphate buffer, pH 7.4, containing 15% glucose and 30% ethylene glycol; 
Sigma-Aldrich).  
Immunohistochemistry  
Sections were rinsed in Tris buffer (50mM Tris, 150mM NaCl, 0.05% Triton X100, pH 7.4) 
3x10 minutes and incubated with primary antibody diluted in Tris buffer with 2% normal goat 
serum (NGS) and Triton X-100 overnight at 4°C under continuous agitation. Sections were 
rinsed 3x10 minutes in tris buffer and incubated with the secondary antibody solution (2% NGS, 
Tris buffer) for 30 minutes at room temperature. Biotinylated secondary antibodies for 
immunoperoxidase staining (Jackson ImmunoResearch Laboratories) were diluted 1:300.   
Target Description Dilution Distributor Procedure 
CD68 rat 1:2000 AbD Serotec IF,  
APP (C-terminal) rabbit 1:60000 Immunogens IF 
Aβ1-40/42 rabbit 1:2000 Millipore/Chemicon IF 
5-HT rabbit 1:5000 Immunostar IF 
TH rabbit 1:3000 Chemicon IF 
Table 1. List of primary antibodies. IF – immunofluorescence. 
After washing 3x10 in Tris buffer, sections were incubated in avidin-peroxidase-complex 
(Vectostain Elite Kit, Vector Labs) for 60 minutes at room temperature. After 3x10 minutes rinse 
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in Tris buffer sections were mounted on gelatinized glass slides, air-dried overnight and 
dehydrated the next day through multiple ethanol and xelene steps and coversliped with.   
Nissl staining  
Air dried coverslips with mounted sections were submerged in the following solutions: 5 min in 
dH2O, 5 minutes in filtered Cresyl violet solution (C18H15N3O3; M 321.34, Fluka BioChemika, 
Cat.no. 10510-54-0), 30 sec in dH2O and cleared in 96% ethanol containing 0.5% acetic acid 
until the desired coloration was obtained, 5 minutes in isopropanol, 5 minutes in 
isopropanol:xylene (1:2) and 4 times dehydrated in xelene for 2 minutes. Afterwards slides were 
coversliped with resinous (Eukitt; Sigma-Aldrich) mounting medium.  
Image acquisition  
For visual assessment of Nissl stainings, 3-4 sections per animal were examined using an 
Axioscop 2 microscope (Carl Zeiss) with bright field illumination with 10x, 20x or 40x 
objectives. Images were acquired with color digital camera (AxioCam MRc5) and a AxioVision 
4.5 software (Zeiss).    
Densitometry  
Intensity of immunoperoxidase staining was measured with densitometry analysis using the 
MCID software (MCID Elite 6.0, Interfocus Imaging Ltd., Cambridge, UK). Images of single 
sections were digitized with a precision illuminator (Northern light Model B95, Imaging 
Research Inc., Brock University, St. Catherines, Canada) and CoolSnap camera (Photometrics, 
Tuscon, AZ, USA) With Micro-Nikkor (55 mm+12 mm) lens (Nikon Corp.) obtained grey 
values were calibrated (Kodak step tablet no 310ST607). The intensity of different regions of 
interest was measured. The individual staining intensity was normalized to the intensity of the 
whole section. 3-4 sections per animal were analyzed.   
Stereology  
Images of individual sections were obtained using Axioplan 2 bright-field microscope (Carl 
Zeiss AG, Feldbach, Switzerland) with 20x lens (air, NA0.75) and a digital camera (MicroFire, 
Optronics AG, Goldbach, Switzerland). The volume of the hippocampus and cerebral cortex and 
number of plaques were estimated with Mercator software (Mercator Pro rev. 7.8.2.; Explora 
Nova, La Rochelle, France).  
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Statistical analysis  
One-way or two-way ANOVA with Bonferoni post-hoc test was performed for multiple 
comparison groups. To compare two groups an unpaired two-tailed t-test was used. Statistical 
analysis was performed in Microsoft Excel and Prism software (GraphPad v.6). 
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Results 
Part 1. Effects of acquired seizures on AD-like pathology in sporadic 
AD mouse model 
To determine whether in AD- susceptible brain, the induction of seizures could trigger AD-like 
pathology reminiscent of the one induced by the second PolyI:C hit (Krstic et al., 2012), the 
offspring of WT mice intravenously injected with PolyI:C at gestational day 17 (GD17) were 
taken into experiments at the age of 3 months and were injected intrahippocampally with KA. At 
the age of 9 or 15 months their brain tissue was collected and immunohistochemically analyzed 
for AD and neuroinflammation markers.  
The extent of the KA-induced lesion and cellular reorganization of the dorsal hippocampus was 
determined by visual assessment of Nissl-stained sections at both time-points, and compared 
with control mice treated with saline instead of PolyI:C (Fig. 1). No phenotypic differences were 
observed at either 9 or 15 months post-KA. 
CD68 was used as a marker to assess the extent of microglial activation. Densitometric analysis 
showed that in both prenatally PolyI:C treated and NaCl treated controls microglial activation 
was elevated and sustained after KA treatment in the ipsilateral hippocampus. There was no 
difference in the extent of microglial activation in both groups of animals at either 9 or 15 
months of age (Figure 2). Tissue was also stained with an antibody recognizing a C terminal 
epitope of APP, labeling all APP isoforms. Densitometric analysis showed that APP-
immunoreactivity was slightly elevated in the granule cells of the dentate gyrus to the same 
extent in prenatally PolyI:C treated and NaCl controls in both 9 and 15 months age groups 
(Figure 3). Interestingly, APP was increased contralateraly in CA1 stratum pyramidale in 
prenatally PolyI:C treated mice in the 15 months group (1.31±0.04, n=6; 1,18±0.02, n=6; mean ± 
s.e.m., P=0.013) (Figure 3, d.).   
 
It is also important to note that generally extensive microglial activation was present at the 
ipsilateral hippocampus up to 12 months after KA injection. 
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Figure 1. Nissl stainings of ipsilateral and contralateral dorsal hippocampus of mice unilaterally 
injected with KA.  KA lesions in prenatally (a,b) and postnatally (c,d) Poly:C treated mice sacrificed at 
9 (a,c) and 15 (b,d) months. Scale bar – 250μm. 
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Figure 2. Effects of acquired seizures on microglial activation in prenatally PolyI:C challenged 
mice. Immunoperoxidase staining for CD68 microglial marker in dorsal hippocampus (a,c) of 9 (a) 
and 15 (c) months old mice injected with kainate. Ipsilateral hippocampi show extensive presence of 
activated microglia typical for the KA injected brain. (b,d) Densitometric analysis of 
immunoperoxidase CD68 staining throughout the layers of dorsal hippocampus of 9 (b) and 15 (d.f) 
months old KA injected animals. Scale bar – 300 μm. 
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Figure 3. Effects of acquired seizures on APP pathology in postnatally  PolyI:C challenged 
mice. Examples of immunoperoxidase staining for C terminal APP in dorsal hippocampus (a,c) of 9 
(a) and 15 (c) months old mice injected with kainate. (b,d) Densitometric analysis of 
immunoperoxidase APP C-term staining throughout the layers of dorsal hippocampus of 9 (b) and 15 
(d.f) months old KA injected animals. Scale abr – 300 μm. 
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Effects of immune challenge on AD pathology in epileptic mice 
To check if epileptic activity together with an immune challenge in the adulthood could induce 
AD-like pathology, WT mice were injected with KA at 3 months of age and 1 month later they 
were intravenously injected with PolyI:C. Mice were sacrificed at 9 and 15 months of age and 
their brain tissue was collected and immunohistochemically analyzed. 
Overall elevation of CD68 microglial marker was observed in all the hippocampal areas in all 
age groups of mice, but was not affected by PolyI:C treatment in adulthood (Figure 4). APP was 
elevated in response to KA injection, but to similar levels in all the treatment groups at both 9 
and 15 months (Figure 5). We did not observe expected immune challenge induced increase in 
APP and CD68 levels in 9 or 15 months group. Such effects of PolyI:C challenge would have 
been fundamental in our experiments and we did not go on further with the analysis of this 
tissue.  
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Figure 4. Effects of immune challenge on microglial activation in mice with chronic 
epileptic activity. Examples of immunoperoxidase staining for C terminal APP in dorsal 
hippocampus (a,c) of 9 (a) and 15 (c) months old mice injected with kainate. (b,d). Scale bar – 
300 μm. 
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Figure 5. Consequences of immune challenge on APP expression in mice with chronic epileptic 
activity. Examples of immunoperoxidase staining for C terminal APP in dorsal hippocampus (a,c) of 
9 (a) and 15 (c) months old mice injected with kainite, prior PolyI:C challenge (b,d). Densitometric 
analysis of immunoperoxidase APP C-term staining throughout the layers of dorsal hippocampus of 
9 (b) and 15 (d.f) months old KA injected animals. Scale bar – 300 μm. 
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Part 2. Effects of acquired seizures on AD-pathology in familial AD 
mouse model 
To understand how recurrent seizures, induced during the pre-plaque stages affect the 
development of AD-like pathology we combined AD and TLE mouse models. To induce life-
long SRS, a group of 3 months old ArcticAβ mice and control littermates were 
intrahippocampally injected with KA. In a first cohort of mutant mice, only 40% survived the 
KA-injection due to strong status epilepticus. Therefore, upon recovery from anesthesia, the 
mice received one intraperitoneal injection of diazepam (5mg/kg) to prevent mortality during the 
KA-induced status epilepticus. Brain tissue was collected 9 months later and was processed for 
immunohistochemistry. In ArcticAβ mice, diazepam fully prevented the immediate (first 24h) 
post-KA mortality; however, in the course of the first 40 days after the KA injection, only 27% 
of injected transgenic mice survived. All the wild-type littermates recovered normally after the 
KA injection and aged till 9 months.   
“Mild” phenotype of KA lesions in ArcticAβ mice 
As a consequence of this mortality, ArcticAβ mice that survived during the experiment had a 
mild KA lesion phenotype, as seen in Nissl-stained sections, represented by degeneration of 
pyramidal neurons in the hippocampal CA1 region limited to the lesion site (Figure 6). Wild-
type animals had the “usual” lesion phenotype, characterized by CA1 degeneration, granule cells 
dispersion and extensive microglial activation. Therefore, the survivors probably received a mild 
initial lesion and might not be truly representative of the whole cohort. 
 
Figure 6. KA lesions in ArcticAβ mice. Nissl staining of dorsal hippocampus typical KA lesions of 9 
months old ArcticAβ mice and WT controls. KA lesions in ArcticAβ have mild phenotype with CA1 
pyramidal cell layer degeneration and no granule cell layer dispersion. Scale bar – 250 μm.  
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Decrease of plaque load in KA injected ArcticAβ mice 
Stereological quantification of Aβ positive plaques revealed their significantly smaller number of 
in both ipsilateral and contralateral (to the KA lesion) hippocampi of ArcticAβ mice in 
comparison to NaCl injected transgenic controls. Hippocampus of KA injected animals had 
significantly lower number of plaques in the ipsilateral side if compared to the contralateral side.  
 
Figure 7. Aβ plaque pathology in KA injected ArcticAβ mice. (a) Immunoperoxidase staining of 
dorsal hippocamopus of ArcticAβ mice injected with either NaCl or KA. Scale bar-250 μm. (b) 
Stereological quatification of the number of plaques in dorsal hippocampous and cortex of ArcticAβ NaCl 
and KA injected mice. (c) Example images of Aβ plaques in the cortex of Arctic mice injected with KA 
or NaCl. Scale bar -150μm (d) Plaque pathology in the hippocampus (ipsilateral) and cortex of ArcticAβ 
injected with NaCl. Scale bar - 50 μm. 
A trend towards a reduced number of plaques was observed in the cortex of ArcticAβ KA 
injected group. But the plaque number did not differ at the ipsilateral and contralateral sides of 
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the cortex within the treatment group (Figure 7).  
 
Figure 8. APP expression in KA injected ArcticAβ mice. (a.) Immunoperoxidase staining for C-
terminal APP of ArcticAβ and WT mice injected with KA or NaCl. Scale bar – 250 μm (b.) Desitometric 
analysis of the staining showing an increase in APP optical density in DG granule cell layer and CA1 
pyramidal cell layer.  
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Effects of KA injection on APP expression on ArcticAβ mice 
As transgenic animals overexpress APP, densitometric analysis of immunostaining against C-
terminal APP showed an increase in the hippocampal granule cell layer and the CA1 pyramidal 
cell layer in ArcticAβ animals in comparison to WT (Figure 8). The analysis of the staining 
showed no differences in changes of APP levels after KA between the between NaCl and KA 
injected ArcticAβ mice.  
Microgliosis in KA injected ArcticAβ mice 
Immunoperoxidase stainings for microglial marker CD68, showed extensive microglial 
activation in the entire ipsilateral hippocampus was present even 6 months after the KA injection 
in WT mice. In ArcticAβ mice activated microglia was only present in degenerating CA1 region, 
but otherwise was not different from NaCl-injected controls (Figure 9). 
 
Figure 9. Microglial activation in response to KA injection in ArcticAβ mice. (a.) Immunoperoxidase 
staining for CD68 in WT and ArcticAβ mice. ArcticAβ mice showing accumulations of microglia around 
Aβ plaques in the cortex and hippocampus (right). Scale bar – 250 μm (b.). Examples of microglial 
accumulations in the cortex of ArcticAβ mice. Scale bar – 50 μm (c.) Dorsal hippocampus of WT (left) 
and ArcticAβ (right) mice injected with KA or NaCl. Scale bar – 250 μm.  
No changes in subcortical innervation in dorsal hippocampus in response to KA treatment 
in ArcticAβ mice with ageing 
Del Tredici and Braak (2013) suggested that Aβ plaques form in the projection zones of 
noradrenergic and serotonergic fibers. We hypothesized that the absence of Aβ plaques could be 
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related to the changes of subcortical innervation of hippocampus, as a result of KA treatment.  
Visual assessment of sections processed for tyrosine hydroxylase and 5-HT immunoreactivity 
revealed that those inputs are not affected at the KA lesion sites in either genotype (Figure 10). 
 
Figure 10.  Noradrenergic and serotonergic fibers in the KA lesioned hippocampi of ArcticAβ mice. 
(a,b) Immunoperoxidase staining for Tyrosine hydroxylase (TH) and (c,d) 5-Hydroxytryptamin (5-HT) of 
the ipsilateral (b,d) and contralateral (a,c) dorsal hippocampus of ArcticAβ mice injected with KA.CA1- 
cornu ammonis; DG – dentate gyrus; H- hilus. Scale bar – 250 μm. 
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Discussion 
In this project, we were looking at the effects of epileptic activity on the development of AD 
pathology in sporadic “double hit” and familial ArcticAβ mouse models.  Inducing seizures in 
prenatally PolyI:C challenged mice, as well as an attempt to exacerbate the effect of seizures by 
a PolyI:C hit in adult mice did not lead to the development of AD-like pathology with ageing. In 
fact, those experiments remain inconclusive because we did not observe the expected age-related 
effects of PolyI:C challenges in non-transgenic mice, which was central to a concept of this 
sporadic AD mouse model.  
ArcticAβ were very sensitive to KA injection and the experimental group had a drastic seizure-
related mortality rate. Surprisingly, KA injected animals at 9 months of age had no plaques in the 
ipsilateral hippocampus and a tendency to decreased plaque load in other brain areas.  
Sporadic AD 
The results of the present study show no effects of induced seizures on the development of AD 
pathology in prenatally immune-challenged mice. Likewise, neuroinflammation and SRS caused 
by KA injection at adult stages could not mimic the effects of the “second hit” of the “double 
hit” PolyI:C mouse model, except for a slight elevation of APP at the contralateral to the 
injection site in PolyI:C prenatally treated mice. SRS and neuroinflammation in TLE KA model 
are localized to the ipsilateral hippocampus. It would be interesting to combine both prenatal and 
adult PolyI:C hits with KA injection to see whether the latter would aggravate AD pathology 
even more.  
Immune challenge that followed KA injection did not lead to AD pathology in WT mice with 
ageing. This result might be interpreted as evidence that a prenatal immune challenge impacting 
on immune system development might be crucial for triggering a later risk to develop AD-like 
pathology.  
Because we could not observe any effect of PolyI:C after either prenatal exposure or postnatal 
injection, the present experiments remain unconclusive. Several reasons might explain a possible 
lack of effect of PolyI:C. For instance, the original PolyI:C experiment was performed in 
C57Bl/6JRcc mouse strain (Krstic et al., 2012), but in our studies we used C57Bl/6JOla mouse 
strain. The latter strain has a spontaneous mutation affecting α-synuclein expression. α-synuclein 
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is a protein present in synaptic terminals throughout the brain and is an important player in the 
development of Parkinson’s disease (Stefanis, 2012). Interestingly α-synuclein is also considered 
to play a role in peripheral immune system (Kim et al., 2004) and could potentially interfere with 
the response of the immune system to PolyI:C.  Another impediment that might have interfered 
with the effects of PolyI:C could be handling of pregnant dams around the injection time. In the 
original “double hit” experiment pregnant females were injected “in house” without any 
additional transport (Krstic et al., 2012). In our case, they had to be transported from the animal 
provider at GD14 before being injected 3 days later. It is known that transport and 
acclimatization affects glucocorticoid levels in rodents (Landi et al., 1982, Tuli et al., 1995). 
Three days of acclimatization could be not enough to stabilize stress hormones levels and this 
could have interfered with the PolyI:C treatment.  
Familial AD 
To test whether induced seizures affect AD-like pathology in a transgenic AD mouse line, we 
mimicked TLE in ArcticAβ mice, that overexpress human APP carrying multiple mutations. In 
comparison to WT, transgenic animals had increased mortality after KA injection. Prevention of 
the initial post-surgical status epilepticus with diazepam delayed, but did not diminish the 
mortality of injected animals. Mice presumably died as a result of seizures within the next 2 
months post KA injection. This unexpected observation suggests that ArcticAβ mice have 
increased seizure susceptibility and lower threshold to status epilepticus development already at 
pre-plaque stages. It was shown that at the age of 2 months, when the mice were injected with 
KA, in the absence of Aβ plaques, intracellular Aβ levels are already elevated, suggesting that 
increase in toxic Aβ species could potentially be epileptogenic. ArcticAβ mice have two FAD 
mutations, namely Swedish and Arctic. Recently, it was shown that mice carrying only Arctic 
mutation (ArcAPP mice) have mild epileptic phenotype in comparison to animals expressing 
APP with Swedish mutation, despite higher APP overexpression (Ziyatdinova et al., 2016). 
Together with ours, this finding underscores the role of increased β secretase activity, 
characteristic for Swedish APP mutation, in epileptogesis in ArcticAβ mice.  
Mice that survived until 9 months of age after KA injection had a “mild” lesion phenotype, that 
could be mainly recognized by the degeneration of CA1 at the injection site in dorsal 
hippocampus. Although, the majority of WT mice had the typical lesion phenotype, with CA1 
degeneration, granule cells dispersion and extensive microglial activation, a few also had a mild 
lesion phenotype, indicating that there is a certain degree of variability in KA injections. Mutant 
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mice with more severe lesions probably died from convulsive seizures during the first month 
after the injection. We assume that the severity of lesions is directly linked to the survival of 
ArcticAβ mice. “Mild” phenotype of KA lesions in 9 months old KA injected group implies 
neurodegeneration and microgliosis limited to the CA1 region of the dorsal hippocampus and it 
was shown that destruction of CA1 may be enough for the development of SRS (Arabadzisz et 
al., 2005, Antonucci et al., 2008). 
 Contrary to our expectations induction of seizures in ArcticAβ mice did not cause an increase in 
Aβ plaque pathology at 9 months. Rather, a tendency towards a reduced number of plaques was 
observed in the cerebral cortex of the ArcticAβ mice, but plaque density did not differ in the 
ipsilateral and contralateral sides of the cortex. In this transgenic mouse line plaques form late 
and rather slowly (Knobloch et al., 2007). Those survivors could be the outliers that would 
normally develop plaque pathology later. A tendency towards reduced plaque pathology in some 
of the injected ArcticAβ mice could in combination with a mild KA lesion contribute to the 
survival of those animals. However, this cannot explain the absence of plaques in the lesioned 
hippocampus. It was proposed (Del Tredici and Braak, 2013) that Aβ plaques form (more or less 
exclusively) in the projection zones of noradreneric and serotonergic fibers originating from 
locus coeruleus and upper raphe nuclei respectively. We hypothesized that if KA lesion causes 
functional and input isolation of ipsilateral hippocampus, this could prevent the Aβ deposition. 
From immunolabeling for TH and 5-HT it turned out that noradrenergic and serotonergic inputs 
are preserved in the ipsilateral and contralateral hippocampi of ArcticAβ and WT mice. This 
disproves our assumption and suggests that the absence of plaques in the ipsilateral hippocampus 
at 9 months is probably a result of local changes induced by KA. Long-lasting 
neuroinflammation triggered by KA at the pre-plaque stages could play a role in the absence of 
plaques in the ipsilateral hippocampus. Apart from microgliosis KA lesion-related 
neuroinflammation is characterized by brain infiltration of peripheral macrophages, an event that 
is in fact shown to be neuroprotective (Zattoni et al., 2011). The characteristic KA induced 
neuroinflammation in young ArcticAβ mice formation could prevent or delay plaque formation. 
The age onset of plaque pathology in ArticAβ mice is 7-9 months (Knobloch et al., 2007). 
Therefore, the group of surviving mice could represent a group of mice in which plaque 
pathology develops later. To check this looking at later timepoints would be beneficial.  
Activated microglia, as visually estimated from the immunostaining for CD68, was observed in 
the ipsilateral hippocampus in ArticAβ mice, but limited only to the degenerating CA1 
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pyramidal cell layer, which was presumably the only area affected by KA treatment in the group 
of surviving mice. As in previous experiments, extensive microglial activation was a prominent 
feature of the ipsilateral KA injected hippocampus in the WT controls.  
Analysis of immunostaining against C terminal APP showed an increase in optical density in 
ArcticAβ mice in comparison to WT controls. This is explained by the overexpression of the 
protein in transgenic mice. APP staining was not denser in the ipsilateral or contralateral 
hippocampus of the transgenics in comparison to the WT controls. To make a solid conclusion 
about the APP expression, limitations of immunolabeling have to be taken into account. To 
confirm this result, it would be interesting to use Western blotting to estimate the levels of APP 
expression.  
Increased sensitivity of ArcticAβ mice to a seizure inducing drug is an intriguing outcome of this 
project, suggesting alterations in synaptic function or in intrinsic properties of neurons in mutant 
mice. Overexcitability could potentially be related to the pathological changes in inhibitory 
system, as a result of APP overexpression that could affect the development of circuitry or the 
production of toxic Aβ species at the ages when mice received KA treatment. The exact 
mechanisms and prevention of such excitability requires further investigation.  
As discussed before, ArcticAβ mice that survive KA injection might represent a group of 
animals with delayed AD pathology development and/or coincident “mild” KA lesion phenotype 
due to variations in injection technique. Being a remarkable outcome, it is also a pitfall of this 
experiment, as it makes it difficult to conclude the effects of seizures on AD pathology. A 
potential solution for this problem, from AD model perspective, would be extending the 
experiment to later timepoints, as looking beyond 6 months post KA, could reveal if the 
survivors represent the group with delayed AD pathology. On the other hand, using transgenic 
AD mouse models that develop AD pathology faster could speed up the obtainment of the 
results. In combination with this, extending diazepam treatment to the first weeks post KA 
injection could also potentially help prevent the mortality. Also, alternatively to KA model, more 
controlled approach towards seizure induction, such that involves for example optogenetics 
could be used (Krook-Magnuson et al., 2015). Abberant neuronal activity was shown in other 
FAD mouse models (Palop et al., 2007, Westmark et al., 2008). In the next chapter, we evaluated 
spontaneous seizure activity in ArcticAβ mice aged up to 15 months. Prospectively, correlating 
spontaneous seizures with the degree of AD pathology in the same animals could give us an idea 
if endogenous seizures could aggravate AD pathology. 
  
 
  
CHAPTER II: ADULT NEUROGENESIS IN ARCTICAβ MICE 
 
 
Mariana Zaichuk
1,2
, Jean-Marc Fritschy
1,2
 
 
 
1
Institute of Pharmacology and Toxicology, University of Zurich, Winterthurerstrasse 190, CH-
8057, Zurich, Switzerland 
2
Neuroscience Center Zurich, University of Zurich and ETH Zurich, Winterthurerstrasse 190, 
CH-8057 Zurich, Switzerland 
 
Part of a submitted publication  
 
 
 
 
 
 
 
 
 
 
Author’s contribution 
All the experimental procedures were carried out by MZ under the supervision by JMF. MZ wrote the manuscript. 
Authors have no conflict of interest to declare. 
. 
Results Study II: Abstract 
44 
Abstract 
Our previous work showed that ArcticAβ mice, which overexpress human APP with double 
Swedish and Arctic mutations, are hypersensitive to intra-hippocampal injection of kainic acid 
(KA), used to model temporal lobe epilepsy. Here, we tested the hypothesis that altered adult 
neurogenesis in these transgenic mice contributes to their hyperexcitability in response to 
convulsants, and thereby seizure propensity in familial AD-mutant mice.  Using pulse labeling 
with BrdU, we observed that ArcticAβ mice have increased precursor cell proliferation, but 
reduced cell survival in the subgranular zone of the hippocampal dentate gyrus, having no net 
effect on the generation of new neurons. As evidenced by retrovirally-mediated eGFP 
expression, we observed that adult born neurons in ArcticAβ mice have decreased number of 
dendritic spines and reduced dendritic branching during their maturation. Therefore, disturbances 
in dendritic maturation might affect the integration of newborn neurons in hippocampal 
networks, implying that the net inhibitory effect of adult neurogenesis would be weakened. This 
alteration could possibly contribute, along with other factors, to the higher sensitivity of 
ArcticAβ mice to seizure-inducing drugs. 
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Introduction 
ArcticAβ mice (Knobloch et al., 2007) are highly sensitive to Kainic acid induced seizures 
(Chapter 1). Unilateral KA injection into the dorsal hippocampus caused severe seizures and 
increased mortality in this mouse model in the first weeks after KA treatment. Sensitivity to 
seizure inducing drugs is not uncommon among FAD mouse models and there is an ongoing 
search for commonalities in those models that can trigger such reactivity.  
Recent studies showed that adult neurogenesis is involved in seizure susceptibility in multiple 
epileptic mouse models. Suppression of neurogenesis can increase the acute effect of KA in mice 
(Iyengar et al., 2015), however, the opposite effect was observed in pilo-carpine epileptic model 
(Cho et al., 2015). Adult neurogenesis was previously shown to be affected in a number of AD 
mouse models (Sun et al., 2009, Biscaro et al., 2012, Wang et al., 2014) and human patients (Jin 
et al., 2004a). Adult-born neurons were previously shown to have a net inhibitory effect on the 
DG-CA3 network (Acsady et al., 1998). Also, it was shown that suppression of adult 
neurogenesis can increase the acute effects of KA in mice (Iyengar et al., 2015).  
Taking these evidences together, we hypothesized that changes in adult neurogenesis in the 
ArcticAβ mice could underlie their increased sensitivity to KA. The series of experiments in this 
project will show whether extensive hAPP overexpression and an increase in toxic intracellular 
Aβ in ArcticAβ mice affect their adult neurogenesis. This study can contribute to our 
understanding of the underlying mechanisms of KA induced seizure susceptibility in this mouse 
model. 
To get basic insights into changes in neurogenesis in ArcticAβ mice we used 5-bromo-2'-
deoxyuridine (BrdU) treatment to look at the proliferation and survival rates and fate 
commitment of newborn cells in the hippocampal subgranular zone. Further, we used 
intrahippocampally injected retrovirus that triggers GFP expression under CAG promoter to 
label newborn cells to analyze the dendritic complexity and morphology and density of spines of 
those cells that were committed to become neurons. 
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Materials and Methods 
Animals  
All experiments performed for this study were carried out in accordance with Swiss law on 
animal experimentation and approved by the Cantonal Veterinary Office of Zurich. Experiments 
were performed with ArcticAβ transgenic mice (Knobloch et al., 2007) and  age-matched wild-
type littermates.  All animals were housed in groups of 2-5 in individually ventilated cages at 
standard conditions (20-24 °C; minimum 40% relative humidity) under a 12-hour light/dark 
cycle, with access to food and water ad libitum.  
Bromodeoxyuridine (BrdU) treatment 
To avoid estrous cycle related effects on adult neurogenesis (Pawluski et al., 2009, Marques et 
al., 2016), three weeks prior BrdU  treatment  adult  female  mice  were  housed  together  at  
highest  density permitted (5 per cage) and bedding containing male mouse urine was introduced 
to the cages to induce Lee-Boot  and  Whitten  cycle-synchronizing  effects respectively 
(Caligioni, 2009, Byers et al., 2012).  At the age of two months on two consecutive days mice 
received two intraperitoneal injections of 90 mg/kg BrdU (Sigma-Aldrich, #B5002, dissolved in 
0.9% NaCl). The tissue was collected at 1 dpi to assess cell proliferation and at 28 dpi to evaluate 
cell survival and cell fate. 
Intrahippocampal virus injection 
Adult male mice (2-3 months old) were anesthetized  by inhalation of 2.5-3% isoflurane (Baxter) 
in oxygen. Retrovirus encoding enhanced green-fluorescent protein (eGFP; total injection 
volume per side - 1 μl)  was  bilaterally  injected  (Nanoject  II,  Drummond Scientific) into  the 
hilus  of  the dentate  gyrus  (stereotactic  coordinates: antero-posterior: -2.0  mm,  lateral:  +/-  
1.5  mm,  dorso-ventral: - 2.3  mm  relative  to Bregma). During surgery and recovery mice were 
kept on a warm pad. After the surgery mice were given an intraperitoneal injection of analgesic 
buprenorphine (Temgesic, Essex Chemicals).  
Tissue preparation for immunohistochemistry 
Brain tissue was collected at 21 and 42 days post injection (dpi). Tissue was collected and 
prepared following the protocol of Notter et al. (2014).  In brief, mice were anesthetized 
(Nembutal; 50 mg/kg;  i.p.)  and perfused intracardially through the left ventricle with 20-25 mL 
of ice-cold, oxygenated aCSF [containing (mM) NaCl 125, KCl 2.5, CaCl2, 3.7, MgCl2 2, 
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NaHCO3 26, NaH2PO4 1.25, glucose  25],  pH  7.4,  at  a  flow  rate  of  10–15  mL/min.  Brain 
was extracted and a block containing hippocampus was immediately immersion-fixed for 3  
hours  in  ice-cold  fixative  [4%  paraformaldehyde  dissolved  in  0.15M sodium phosphate 
buffer, pH 7.4). Tissue was then rinsed with PBS (pH = 7.4) and cryoprotected overnight in 30% 
sucrose in PBS at 4°C.   
Fixed and cryoprotected tissue was sectioned into 40μm (BrdU+ experiment) or 70μm (eGFP 
experiment) thick serial coronal sections using tissue mounting fluid (M-1 Embedding matrix, 
Shandon, Thermo Scientific, USA) and freezing sliding microtome (MICROM HM 400, 
MICROM International GmbH, Walldorf, Germany) at -40°C and collected into ice-cold PBS. 
For long-term storage, sections were transferred into cryoprotectant solution (50mM sodium 
phosphate buffer, pH 7.4, containing 15% glucose and 30% ethylene glycol; Sigma-Aldrich) and 
kept at -20°C.  
Immunohistochemistry 
For immunofluorescence, sections were washed three times in PBS (pH 7.4, 10 min each) and 
incubated overnight (BrdU experiment) or for 72 hours (eGFP experiment at 4°C under 
continuous agitation with primary antibodies diluted in Tris buffer (50mM Tris, 150mM NaCl, 
0.05% Triton X-100, pH 7.4) containing 2% normal goat serum (NGS) or normal donkey serum 
(NDS) and 0.2% Triton X-100.  Afterwards sections were rinsed three times in PBS and 
incubated in secondary antibody solution (2% NGS, Tris buffer) for 30 min (BrdU experiment) 
or 6 hours (eGFP experiment) in darkness, at room temperature, under continuous agitation, with 
secondary antibodies raised in goat.  Secondary antibodies conjugated to AlexaFluor-488 
(Invitrogen) were diluted to 1:1000 and those conjugated to Cy3 or Cy5 (Jackson 
ImmunoResearch Laboratories) to 1:500.  After washing, three times with PBS, sections were  
mounted on  gelatin-coated  glass  slides  and  cover-slipped  using  Dako Fluorescence  
Mounting Medium  (Agilent Technologies, Santa Clara, CA, USA).  Tissue was kept in the dark 
at 4°C prior imaging.   
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Target Description Dilution Distributor Procedure 
Primary 
BrdU rat 1:5000 Oxford Biotech IF, IP 
NeuN mouse 1:1000 Chemicon IF 
GFAP rabbit 1:20000 Dako IF 
GFP chicken 1:5000 Aves Labs Inc. IF 
Secondary 
rat donkey, Alexa 488-conjugated 1:1000 Jackson Immuno 
Research Inc. 
IF 
mouse  donkey, Cy3-conjugated 1:500 Jackson Immuno 
Research Inc. 
IF 
rabbit donkey, Cy5-conjugated 1:500 Jackson Immuno 
Research Inc. 
IF 
chicken goat, Alexa 488- conjugated 1:1000 Jackson Immuno 
Research Inc. 
IF 
Table 1. List of primary and secondary antibodies used for immunohistochemistry.  
Making BrdU available to primary antibodies required pre-treatment prior immunoperoxidase or 
immunofluorescence staining. Free-floating sections were incubated in 0.2N HCl for 5 minutes 
at room temperature, before being transferred into 4N HCl for 30 minutes at 37°C. Right 
afterwards and before immunostaining, sections were rinsed twice in PBS and twice in Tris-
Triton. For immunoperoxidase staining, biotinylated secondary antibodies (Jackson 
ImmunoResearch Laboratories) were diluted 1:300 and after washing three times in Tris buffer, 
incubated with avidin-peroxidase-complex solution (Vectastain Elite kit, Vector Labs) at room 
temperature.  After washing three times in Tris buffer, sections were stained by combining 3,3-
diaminobenzidine (DAB; Sigma–Aldrich Inc.) in Tris buffer (pH 7.7) with hydrogen peroxide 
for 5-15 min. Sections were immediately transferred to ice-cold PBS and washed three times.  
Finally, sections were mounted onto gelatinized glass   slides,   air-dried  overnight, dehydrated 
with ethanol, cleared in xylene and cover-slipped with resinous (Eukitt™; Sigma-Aldrich) 
mounting medium. 
 
 
Results Study II: Materials and Methods 
49 
Image acquisition and analysis 
Stereological analysis 
BrdU
+
 cells  in  the  subgranular  zone  (SGZ)  and  granule  cell  layer  (GCL)  of  the  dentate  
gyrus were counted in 4-5 sections per mouse in dorsal hippocampus using Axioscop, (Zeiss, 
Jena, Germany)  40x  oil-immersion  lens,  NA  1.3.  Dorsal hippocampal volume was estimated 
using Mercator software (Mercator Pro rev. 7.8.2, Explora Nova, La Rochelle, France). BdrU
+ 
cells in the DG SGZ were quantified manually.  
Sholl analysis 
Fluorescent Z-stacks (spaced by 0.7 μm) throughout the entire thickness of the section were 
acquired with were acquired with confocal microscope LSM710 using 40x (NA, 1.4) oil 
immersion objective and ZEN 2012 black edition (Carl Zeis MicroImaging GmbH, Goettingen, 
Germany) software. Images were analysed with ImageJ (version 1.49o; Java 1.6.0_12 (Wayne 
Rusband, National Institutes of Health, USA). Sholl analysis (Sholl, 1953) was used to analyze 
the complexity of the dendritic trees. Complexity if dendritic tree was equivalent to the number 
of intersection of dendrites with concentric circles spaced by 10μm intervals, centered on the cell 
body.  First, neurons were traced using NeuronJ plugin (NIH ImageJ; Meijering  (Meijering et 
al., 2004)). Further Sholl analysis macro (Anirvan Ghosh Laboratory, University of California, 
San Diego, La Jolla, CA,  USA)  was used to calculate  the  numbers  of  intersections between  
dendrites  and  concentric  circles. For the number of intersections as a function of distance from 
the soma, area-under the curve (AUC) was calculated and used for further statistical analysis. 
Dendritic morphometry (primary dendrite length, total dendrite length) was assessed with the 
NeuronJ plugin. In total 14-31 cells from the groups of 5 to 8 mice per time point were analyzed.    
Spine density analysis 
Z-stacks for spine density and morphology analysis of randomly selected eGFP-positive 
dendritic segments were acquired with 40x oil immersion objective using 2.7 digital zoom factor. 
Spines density quantification and manual spine type classification were performed using ImageJ 
plugin Cell Counter. No distinction was made between spine and filopodia. The length of each 
segment was measured and the number of spines/μm was quantified with Excel.  
Statistical analysis 
Data is shown as mean ± standard error of the mean (s.e.m.). An unpaired, two-tailed, Student’s 
t-test was used to compare two groups. Statistical analysis and graphs were plotted with Prism 
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software (GraphPad Software Inc., La Jolla CA, USA, version 6). Figures were designed with 
Abobe Illustrator CSS 15.1.0.  
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Results 
Proliferation and survival of adult newborn cells are affected in ArcticAβ mice 
BrdU labelling experiments were performed in adult ArcticAβ mice and wild-type controls. 
BrdU ip injections were performed on two consecutive days and tissue was collected at 1 and 28 
dpi (days post injection) (Figure 1.a). Collected brain tissue was further immunostained for BrdU 
and BrdU
+
 cells were stereologically quantified. At 1 dpi there was a significant increase of 
BrdU
+
 cell density in the subgranular zone of the hippocampal dentate gyrus of ArcticAβ 
compaired to wild-type mice (14039 ± 1243 cells/mm
3
, n=8 10415 ± 728 cells/mm
3
, n=8; data 
shown as mean ± s.e.m.; P=0.821, paired, two-tailed Student’s t-test). This indicates higher NPC 
proliferation rate in ArcticAβ mice (Figure 1.b,c). At 28 dpi there was no difference observed 
between the BrdU
+
 cell density in the SGZ between the genotypes (ArcticAβ: 2663 ± 261.8 
cells/mm
3
, n=9; wild-type: 3384 ± 491 cells/mm
3
, n=9; data shown as mean ± s.e.m.; P=0.214, 
paired, two-tailed Student’s t-test), suggesting a decreased survival rate of NPC in ArcticAβ 
mice (Figure 1.b,c). Increased NPC proliferation is consistent with some of the earlier reports 
from FAD mouse models, specifically those that also overexpress APP (Jin et al., 2004a, Gan et 
al., 2008) and with data from AD patients (Jin et al., 2004b). Long-term survival of NPCs was 
reported decreased in several hAPP transgenic lines and in AD brains (Haughey et al., 2002, 
Boekhoorn et al., 2006, Donovan et al., 2006, Verret et al., 2007, Li et al., 2008). Increased 
proliferation could be ascribed to the increased levels of soluble APP (sAPP) that was shown to 
regulate NPC proliferation (Demars et al., 2011, Lazarov and Demars, 2012, Demars et al., 
2013) and/or to the compensatory mechanisms due to the elevated toxic Aβ species in neurons at 
this age of animals.  
Neuronal vs astrocytic fate commitment was not affected in ArcticAβ mice with 89-91% being 
positive for neuronal marker NeuN, 6-7% being positive for astrocytic marker GFAP and about 
3% not labelled for either NeuN or GFAP (commited to become microglia) (Figure 1.d).  Similar 
ratios were reported in previous studies from our lab for WT (Duveau et al., 2011a).  
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Figure 1. Differences in newborn cell proliferation and survival between wild-type and ArcticAβ 
mice. 
(a) Schematic representation of the experimental design. Mice received BrdU injections on two 
consecutive days and brain tissue was collected at day 1 and 28 post BrdU injection to evaluate cell 
proliferation and survival rate in the DG respectively. (b) Representative images of BrdU immunostaining 
1 and 28 days after the second BrdU treatment. BrdU
+
 cells were located in the inner part of the GCL. 
Higher density of BrdU
+
 cells was common in ArcticAβ mice at 1 dpi, but there were no differences at 28 
dpi between two genotypes (scale bar - 160μm).  (c) Unbiased quantification of BrdU+ cells in both 
genotypes. ArcticAβ mice have a significantly increased proliferating cell density at 1 dpi. Density of 
BrdU
+
 cells was not different between two genotypes at 28 dpi. (*P>0.05, unpaired t-test).  (d) Triple 
immunofluorescent staining for BrdU, NeuN and GFAP to differentiate BrdU
+
 neurons and astrocytes 
showed no difference in neurogenesis vs gliogenesis in ArcticAβ mice. 
 
Dendriric arborization is reduced in ArcticAβ mice 
Next, we investigated dendritic arborization of newborn granule cells using retroviral labeling 
technique. eGFP- encoding retrovirus was stereotactically injected in the dorsal hippocanmpus of 
wild-type and ArcticAβ adult mice. The virus incorporates into the dividing cells and thus the 
day of the injection marked the birthday of the neuron. Brain tissue was collected for further 
analysis at day 21 and 42 post-injection and immunostained for signal enhancement for eGFP for 
further confocal imaging (Figure 2.b.). Neurons were readily discriminated from dividing 
astrocytes and microglia by their distinct morphology and location. 21 and 42 dpi cover 
immature and mature stages of neuronal development (Figure 2a.). Complexity of dendritic 
arborization was estimated using Sholl analysis (number of intersections with concentric circles 
centered on the soma).  There was overall tendency towards reduced dendritic arborization at 
both 21 and 42 dpi in ArcticAβ mice, however further away from soma, starting from 150μm this 
difference was statistically significant (at 21 dpi wild-type: 197.4 ± 31.29, N=27; ArcticAβ: 
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69.64 ± 23.31 N=14; P=0.0094, at 42 dpi wild-type: 359.0 ± 24.77 N=31, ArcticAβ: 257.7 ± 
33.91 N=15, P= 0.0221; data displayed as area under the curve (AUC) mean ± s.e.m., paired, 
two-tailed Student’s t-test) (Figure 2.c,d).  
 
 
Figure 2. Reduced dendritic arborization in ArcticAβ newborn neurons. 
(a) Schematic representation of the experimntal design. Brain tissue of both genotypes was collected 21 
and 42 days after the intrahippocampal injection of eGFP retrovirus (left). Quantification of dendrtitic 
arborization of eGFP+ adult-born neurons was done by Sholl analysis that measures the number of 
intersections between eGFP+ dendrites and virtual concentric circles centered on the cell body and spaced 
by 10μm (right). (b) (b’-b’’’’) Fluorescent images of representative examples of eGFP+ cells in each 
genotype at 21 (b’,b’’) and 42 (b’’’,b’’’’) dpi (Scale bar – 50 μm). (c,d) Quantitative result of Sholl 
analysis showed no significant difference, but a trend towards reduced dendritic arborisation in ArcticAβ 
at 21 dpi in comparison to wild-type. There were no differences between genotypes at 42 dpi. 
 
Spine density is reduced in ArcticAβ mice 
 
Further, we analyzed overall spine density and spine morphology between wild-type and 
ArcticAβ mice at 21 and 42 dpi. Mushroom, stubby and thin spines correspond to immature and 
mature types respectively. Overall and mature type (thin) spine density were reduced in 
ArcticAβ mice at 21 dpi, indicating abnormal neuronal maturation. This difference was not 
present at 42 dpi, where only the density of stubby spines was reduced in mutant mice, 
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suggesting possible delayed development of newborn neurons in ArcticAβ mice (Figure 3.a,b; 
Table 1). There was no significant difference in proportions of spine types at 21 (wild-type – thin 
76%, stubby 15%, mushroom 9%; ArcticAβ – thin 74%, stubby 17%, mushroom 9%) and 42 dpi 
(wild-type – thin 65%, stubby 26%, mushroom 9%; ArcticAβ – thin 71%, stubby 21%, 
mushroom 8%) (Figure 3.c).  
Our results go in line with previous research on a similar FAD mouse model that exhibited 
abnormal morphological development at later neuronal developmental stages (Sun et al., 2009). 
Our experiments were performed in 2-3 months old mice. At this age, there are still no amyloid 
plaques accumulated, but Aβ is shown to already increase intracellularly (Knobloch et al., 2007).  
hAPP-I5 mice that have high hAPP levels, but relatively low Aβ levels exhibit normal adult-born 
GC development (Mucke et al., 2000). Taking this into account, it’s likely that in ArcticAβ mice 
elevated Aβ levels, but not hAPP overexpression could be held responsible for the abnormalities 
in dendritic arborization, Sun et al. showed that dendritic spine density was increased at early 
developmental stages, but went down in hAPP-J20 mice after 28 dpi. hAPP-J20 mice 
overexpress hAPP with Indiana and Swedish mutations (Mucke et al., 2000). The latter they 
share with ArcticAβ mice, that additionally have hAPP Arctic mutation. The role of hAPP 
mutations could also not be completely excluded and could explain the differences in adult  
 
Table 1. Spine density and statistical analysis.  
Numerical data of mushroom, stubby, thin and overall spine density (spines per μm) in wild-type and 
ArcticAβ mice at 21 and 42 dpi. Data displayed as mean ± s.e.m. There were significantly more thin and 
generally all spines in wild-type vs ArcticAβ mice at 21 dpi. At 42 dpi there was significant difference in 
stubby spines in wild-type vs ArcticAβ. Statistical test - paired, two-tailed Student’s t-test.
21 dpi WT ArcticAβ significance, p value 
Mushroom 0.059 ± 0.006, n=27 0.044 ± 0.008, n=14 not significant, 0.164 
Stubby 0.102 ± 0.016, n=27 0.076 ± 0.016, n=14 not significant, 0.298 
Thin 0.508 ± 0.037, n=27 0.316 ± 0.032, n=14 significant, 0.002 
All 0.669 ± 0.511, n=27 0.435 ± 0.044, n=14 significant, 0.005 
42 dpi WT ArcticAβ significance, p value 
Mushroom 0.096 ± 0.010, n=18 0.084 ± 0.009, n=18 not significant, 0.415 
Stubby 0.301 ± 0.037, n=18 0.220 ± 0.015, n=18 significant, 0.052 
Thin 0.728 ± 0.057, n=18 0.732 ± 0.062, n=18 not significant, 0.965 
All 1.126 ± 0.085, n=18 1.037 ± 0.069, n=18 not significant, 0.419 
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neurogenesis in those models. Arctic mutation promotes higher rate of Aβ40 protofibril formation 
(Nilsberth et al., 2001). Indiana mutation leads to an increase of Aβ40/Aβ42 ratio (Tamaoka et al., 
1994). Differences in the amount of more toxic Aβ species and/or increased Aβ40 toxicity, could 
account for those differences in spine development.  
 
Figure 3. Reduced spine density in newborn neurons in ArcticAβ mice. 
Dendritic spine classification analysis. (a) Representative images of dendritic segments from eGFP 
expressing GCs of wild-type and ArcticAβ mice at 21 and 42 dpi (Scale bar – 5 μm).  (b) Quantification 
of mushroom, stubby, thin and overall spine density. ArcticAβ mice had significantly reduced overall 
spine density and specifically thin spine density at 21dpi and reduced stubby spine density at 42 dpi with 
no difference in overall spine density. (c) There were no significant differences between the proportions 
of all three types of spines between the two genotypes. 
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Conclusion 
Using BrdU labelling we found that ArcticAβ mice have increased proliferation rate, but 
decreased survival of NPCs. Neurogenesis vs gliogenesis cell fate was not affected in the 
transgenic animals. This result is consistent with many reports from other FAD mouse models 
and also from humans (Jin et al., 2004a, Jin et al., 2004b, Gan et al., 2008). FAD mouse models 
that overexpress human APP, ArcticAβ mice included, tend to have have increased NPC 
proliferation, which is probably related to high amounts of soluble APPα (sAPPα), a proteolyte 
of APP processing. sAPPα was reported to increase adult projenitor cells proliferation (Demars 
et al., 2011, Demars et al., 2013). 
 
Next, with viral eGFP labeling of newborn cells we showed that ArcticAβ mice have decreased 
dendritic tree complexity and have decreased spine density during maturation in comparison to 
wild-type. This morphological result is for the most part consistent with what has been shown for 
hAPP-J20 FAD mice (Sun et al., 2009). In this study, the authors used electrophysiological 
techniques to show that disbalance of GABAergic and glutamatergic inputs in the mouse model 
is the reason for the alterations in the development of the newborn neurons. hAPP-J20 and 
ArcticAβ mice have double Swedish mutation in common, which is immediately adjacent to the 
β-secretase site in APP sequence and results in increase of total Aβ levels. It would be interesting 
to check if impairments in neurogenesis could be rescued with antiAβ antibodies treatment. 
Adult-born neurons were suggested to have a net inhibitory effect on the DG-CA3 network, by 
extensive innervation of interneurons (Heinemann et al., 1992, Lothman et al., 1992, Acsady et 
al., 1998, Hsu, 2007, Ikrar et al., 2013, Iyengar et al., 2015). Alterations that occur during 
maturation in adult born neurons in ArcticAβ mice can lead to inappropriate circuit integration 
and lead to weakening of the overall inhibition in DG-CA3 network, which could decrease 
seizure threshold in ArcticAβ mice.  
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Abstract 
Dysfunction of interneurons underlies a variety of CNS disorders, including Alzheimer’s disease 
and epilepsy. GABAergic interneurons control the firing and synchronization of principal 
neurons, thereby driving network oscillatory activity. This study expands our understanding of a 
unique inhibitory synapse strengthening mechanism, first observed in cerebellar stellate 
interneurons and triggered by mitochondrial reactive oxygen species (mROS). mROS is 
traditionally associated with oxidative stress and its harmful effects. In addition, however, mROS 
plays an important physiological role in signaling. The production rate of mROS reflects 
dynamic metabolic demand of a neuron, and, therefore its level of activity. mROS triggers a 
cascade of signaling events that lead to strengthening of inhibitory transmission by recruiting 
more GABAA receptors (GABAAR) at postsynaptic sites, providing a protective feedback 
mechanism in case of overactivation. Interestingly, the recruited receptors have distinct 
biophysical properties compared to the predominant resident receptor type, due to a different 
subunit composition.  In this study, we further explored this form of plasticity and demonstrate 
that repeated high frequency stimulation (HFS) of input fibers, used to strongly activate stellate 
cells in brain slices, leads to un-silencing of a distinct pool of GABAARs in stellate cells. Such 
inhibitory postsynaptic currents IPSCs with distinct kinetic properties could be detected by 
comparing evoked responses to a minimal stimulation before and after HFS, suggesting 
recruitment of additional GABAARs to postsynaptic sites.  We show that the mechanism of this 
recruitment is likely postsynaptic and involves mROS, since the effect of HFS could be strongly 
attenuated by an antioxidant present in the recording pipette. Interestingly, the effect of HFS was 
variable among the recorded stellate cells, suggesting that different types of responses might 
correspond to different origin of synaptic inputs onto stellate cells. The next steps will be to 
identify the exact signaling pathways that underlie this synaptic strengthening, in order to mimic 
their action pharmacologically, and to identify endogenous stimuli or molecules inducing this 
form of plasticity. 
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Introduction 
Neuronal synapses play a central role in signal transmission and transduction in the CNS. Their 
variety and the wide range of mechanisms by which they can be modified form the basis of 
neuronal plasticity. There are synapses that under basal conditions are not taking part in 
neurotransmission and form a “reserve pool” that can be activated under specific circumstances.  
Almost two decades ago, so called silent synapses were first described in the CA1 area of the 
hippocampus. (Isaac et al., 1995, Liao et al., 1995). These synapses are not eliciting excitatory 
postsynaptic currents (EPSCs) at the resting membrane potential, but do so upon depolarization. 
AMPARs are conducting currents at the resting membrane potential. Activation of NMDARs 
requires depolarization to remove magnesium block. Glutamatergic synapses are „silent“ if they 
contain only NMDARs and no AMPARs; under physiological conditions are not mediating 
synaptic transmission. Synapses become un-silenced upon application of high frequency long-
term potentiation-inducing stimulation in combination with depolarization; AMPA receptors are 
possibly trafficked to those synapses under these conditions. Since the discovery of silent 
synapses, their role in synaptic plasticity and strengthening, as well the physiological 
mechanisms of un-silencing were extensively studied. Silent synapses were subsequently 
described in many other brain regions (Kerchner and Nicoll, 2008).  
 
Silent synapses are not necessarily excitatory. Paired recordings of goldfish brainstem Mauthner 
cells, and their presynaptic partners, local glycinergic interneurons, revealed that transmission 
failed to occur in many cases in response to external stimulation. Series of titanic stimulation un-
masked these synapses, providing evidence for one type of long-term potentiation at inhibitory 
synapses (Korn et al., 1992). 
 
Rebound potentiation at the cerebellar Purkinje cells (PCs) is another classical example of 
inhibitory synaptic plasticity in the CNS (Kano et al., 1992). It is characterized by an increase in 
inhibitory postsynaptic currents (IPSCs) amplitude following PC depolarization. This type of 
synaptic plasticity relies specifically on β2-GABAA receptors that are predominant at somatic PC 
synapses originating from basket cells (BCs) and on the activity of CAMKII. Rebound 
potentiation is an important regulator of PC spontaneous firing and is crucial for temporal coding 
of PC output and the level of inhibition of deep cerebellar nuclei (Hirano et al., 2016). 
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Recent research has shown that elevation of mitochondrial reactive oxygen species (mROS) can 
also lead to strengthening of inhibitory transmission at GABAergic stellate interneurons in the 
cerebellar molecular layer, apparently by increasing the number of functional GABAergic 
synapses by a postsynaptic mechanism. The rate of mROS production is reflecting the metabolic 
state of the cell. Increased neuronal firing elevates mROS and can lead to the recruitment of new 
receptors to the synapse. α1 subunit-containing GABAARs were long thought to be the 
predominant subtype of GABAARs expressed in stellate cells; however, there is strong evidence, 
that mROS mediates synaptic strengthening by indirectly recruiting α3 subunit-containing 
GABAARs to the postsynaptic membrane (Accardi et al., 2014). Underlying mechanisms of this 
process are still being investigated.  
 
The aim of this study is to investigate whether similarly to silent synapses, a synaptic reserve 
pool containing α3-GABAARs can also be un-silenced under specific conditions. We stimulated 
input fibers in the vicinity of recorded stellate cell with high frequency stimulus (HFS). Before 
and after a series of HFS we recorded evoked IPSCs in a stellate cell using minimal stimulation 
approach (Isaac et al., 1995) to demonstrate the un-silencing of the synapses. The intensity of 
minimal stimulation for each recording is established before the series of HFS and is supposed to 
evoke 20-50% of IPSCs.  After the un-silencing stimulus (HFS in this case) we looked at the 
changes in the number of evoked IPSCs and their kinetics. HFS puts a cell into a high energy 
demanding mode, which can trigger mROS production. We expect to see the rise in evoked 
IPSCs after a series of HFS.  
 
Insulin is known to increase mROS in neurons, by which mechanism it can induce synaptic 
strengthening at cerebellar granule cells through activating a cascade of events that recruits α6-
GABAARs to postsynaptic sites, where α1-GABAARs are predominant (Accardi et al., 2015). 
We were curious to test whether this mechanism can be generalized to other cell types and might 
lead to strengthening inhibitory transmission in stellate interneurons as well. Thus, we tested the 
effect of insulin by whole-cell patch clamp recording of miniature IPSCs in stellate cells. 
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Materials and Methods  
Animals 
Wild-type mice with C57BL/6J genetic background (Charles River laboratories) were 
maintained as a breeding colony at McGill University (Montreal, Quebec, Canada). Both males 
and females were used for experiments. α3-KO mice were maintained at C57BL/6J background 
(B6.129 1-Gabra3tm2Uru/Uru) and bred at McGill University.   Only α3-KO male mice were 
genotyped by PCR analysis of tail biopsies and further used in the experiments. The age of 
animals used in those experiments varied between 15 and 28 days. All experiments have been 
approved by the local authorities and were performed in accordance with the guidelines of the 
Canadian Council on Animal and were approved by the Animal Care Committee of McGill 
University (Protocol Number: 4564).  
Cerebellar slice preparation 
Mice were anesthetized with Isoflurane and immediately decapitated. Cerebellum was rapidly 
detached from the brain and extracted into an ice-cold oxygenated (95% O2,5% CO2) cutting 
solution, containing (in mM): 235 sucrose, 2.5 KCl, 1.25 NaH2PO4, 28 NaHCO3, 0.5 CaCl2, 7 
MgSO4 and 28 D-glucose (pH of  7.4; osmolarity of 305– 315 mOsmol/L). Cerebellar tissue was 
fixed on the stage of the vibrating tissue slicer (Leica VT1200) cutting chamber with medical 
glue. The cutting chamber was filled with the ice-cold cutting solution, which was oxygenated 
(95% O2, 5% CO2) during the entire slice preparation procedure. Each 300 μm thick cerebellar 
vermis slice was immediately transfered into oxygenated, room temperature (20–23 °C) artificial 
cerebrospinal fluid (aCSF) that contained (in mM): 125 NaCl, 2.5 KCl, 1.25 NaH2PO4, 26 
NaHCO3, 2 CaCl2, 1 MgSO4 and 25 D-glucose (pH of 7.4; 305–315 mOsmol/L). Recordings 
started not earlier than 1 hour after the slice preparation.  
Electrophysiology 
Whole-cell patch clamp recording were performed on the stellate interneurons, visually 
identified according to their cell body size (8-9 μm) and location in the outer two-thirds of the 
molecular layer. Recordings were obtained on two electrophysiological setups, equipped with an 
Olympus BX51 upright microscope (Olympus) both utilizing differential interference 
contrast/infrared optics. Patch pipettes were prepared from thick-walled borosilicate glass 
(GC150F-10, OD 1.5 mm, ID 0.86 mm; Harvard Apparatus) with PC-10 pipette puller 
(Narishige). Patch pipettes has open tips resistances of 5-10 MΩ when filled with intracellular 
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solution that contained (in mM): 140 CsCl, 4 NaCl, 0.5 CaCl2, 10 HEPES, 5 EGTA, 2Mg-ATP, 
2 QX314 to block voltage-activated Na+ channels (pH of 7.4 adjusted with CsOH, osmolarity of 
300–310 mOsmol/L).  
Recordings were obtained with Multiclamp 700A amplifier (Molecular Devices, Sunnyvale, CA, 
USA) at a holding potential of -60mV. Series resistance and whole-cell capacitance were 
estimated by cancelling the fast current transients evoked at the onset and offset of brief (10–20 
ms) 5mV voltage-command steps. Series resistance (10–35 MΩ) was compensated at 40% and 
monitored for stability throughout the experiments. Currents were filtered at 5 kHz with an eight-
pole low-pass Bessel filter (Frequency Devices, Haverhill, MA, USA) and digitized at 25 kHz 
with a Digidata 1322A data acquisition board and Clampex9 (Molecular Devices). The 
capacitance of the stellate cells was in the range of 6–11 pF. The bath was continuously perfused 
with aCSF at room temperature (22–23°C) at 1–2 ml/min flow rate. Minimal stimulation (MS) 
experiments were performed in the presence of GYKI to block AMPA receptor currents. mIPSCs 
were recorded in the presence of TTX (1 mM) in the aCSF.  
For extracellular stimulation aCSF filled thin-walled borosilicate glass electrodes (OD 1.65 mm, 
ID 1.15 mm; King Precision Glass Inc., Claremont, CA, USA) with a tip current of < 3 MΩ were 
used. A platinum wire wrapped around the stimulation electrode served as the ground electrode 
for the stimulation circuit. After a stable whole-cell patch was obtained, the stimulating electrode 
was positioned in the outer two-thirds of the molecular layer beneath the slice surface, 50 to 100 
μm away from the cell body. Voltage pulses (15-30 V in amplitude, 200–400 ms in duration) 
were applied at low frequency (0.1 Hz) through the stimulating electrode to identify if the 
stimulation is evoking IPSCs.  
The voltage intensity used, was the lowest necessary to obtain 100% success (I100) in evoking 
IPCSs. Stimulation voltage intensity was lowered until the success rate was in the range of 25-
75% and this value would be noted (I50) as the intensity for minimal stimulation (MS) protocol. 
GYKI was washed in with the perfusing aCSF, which was followed by two control 5 minute 
long recordings at 0.1Hz at I100. If the evoked events visibly decreased (about 50%) due to the 
action of GYKI, it would confirm that the interneuron has preserved glutamatergic inputs and 
this cell would be further used in the experiment. Minimal stimulation lasted five minutes at 0.5 
Hz frequency with I50,  at Vm = -60 mV. First control MS recording was followed by high 
frequency stimulation (HFS) (6 pulses at 100 Hz repeated 3 times in 1 minute) at I100 at Vm = 
+40 mV. Series of alternating HFS and MS were repeated five times. Recording time for each 
experiment lasted 45 minutes.  
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Analysis 
Curve fitting and figure preparation of all electrophysiology data were performed with Origin 7.0 
(OriginLab), Microsoft Excel, Clampfit 10 (Molecular Devices). The decay phase of evoked 
IPSCs were fit with a single exponential curve, mIPSCs were analyzed with Strathclyde 
Electrophysiology WinWCP and WinEDR (John Dempster) software. mIPSCs detection 
threshold was of four times the mean root square noise level. Detection of mIPSCs was visually 
confirmed for quality control. All data are expressed as mean ± s.e.m.; P-values represent the 
results of paired, two-tailed Student’s t-tests. A P-value of less than 0.05 was considered 
statistically significant.  
Pharmacological compounds 
GYKI 53655 (10 µM) was purchased from Tocris. Insulin (0.5 µM, Sigma) was prepared from a 
163 µM stock that required 0.1 M acetic acid to ensure complete dilution. TTX (1 mM) was 
purchased from Alomone Labs (Jerusalem, Israel). Stock solutions of these reagents were 
prepared in water and were stored at -20 °C and working solutions were diluted with aCSF 
shortly before application into the bath. The antioxidant, NAC (1 mM) (Sigma) was prepared as 
a stock solution in water and dissolved in patch electrode solution on the day of the experiment. 
Mg-ATP was included in our patch electrode solution to avoid compromising Na
+
/K
+
 ATPase 
function. 
  
Results Study III: Results 
64 
Results  
Repeated high frequency stimulation of input fibers strengthens GABAergic synaptic 
transmission in stellate interneurons 
To strengthen GABAergic transmission in stellate cells, we used repeated high frequency 
stimulation (HFS) of the molecular layer and used a minimal stimulation paradigm to reveal the 
occurrence of additional GABAA receptor-mediated IPSCs. Minimal stimulation allows 
recording the postsynaptic response elicited from only a few synapses activated by a weak 
electrical stimulus. The stimulating electrode was positioned at the upper third of the molecular 
layer of the cerebellum in the vicinity (50-100 µm) of the clamped interneuron. The stimulus 
intensity was set at amplitude that evoked 25-75% of successful responses, the rest of stimuli 
failed to evoke a postsynaptic response.  
 
 
Figure 1. Experimental setup for recording evoked inhibitory events using minimal stimulation 
approach in combination with high-frequency stimulation.  
(a) Recordings were obtained from stellate interneurons, located in the upper two thirds of the cerebellar 
molecular layer. Stimulating electrode was positioned 50-100µm away from the patched cell body. (b) 10 
minutes following GYKI application, pre-HFS control MS recording was obtained, following by a series 
of 5 alternating HFS and MS pairs. (c) Example of MS recording, single sweeps recorded for 5 minutes 
superimposed. (d) Single 5 minute long MS recording windows spaced by HFS stimuli. Black dots 
represent the amplitudes of the responses over time.  
 
To mimic a physiological stimulus altering the metabolic state of the cell in a way that increases 
mROS production, we used repeated HFS of afferents to the recorded interneuron. The 
stimulation protocol was applied five times interspaced by five minute long minimal stimulation 
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recordings (Figure 1). The percentage of transmission failures after minimal stimulation was 
compared at the beginning and the end of the 45 minute recording period. 
 
Analysis of the recordings revealed that, on average, the failure rate of  evoked IPSCs was 
significantly decreased following the series of HFSs by the end of the experiment in the majority 
of recorded cells (52.24 ± 5.8%, before and 25.8 ± 4.4% after the HFS, mean ± s.e.m.; n=8, 
P=0.003, paired, two-tailed Student’s t-test) (Figure 2c). Visual inspection of the traces 
suggested that the majority of evoked responses by the end of the recording had amplitude 
smaller than 200 pA.  Thus, we compared the average amplitude of this group of responses to 
those seen at the beginning of experiment and observed a significant increase. For instance, 
average amplitude of the responses at the end of the experiment normalized to the average 
amplitude at the beginning of experiment was 1.59 ± 0.2, (arbitrary units (a.u.), mean ± s.e.m.; 
n=8). Responses with amplitudes larger than 200pA did not significantly differ in the beginning 
and at the end of the experiment (1.03 ± 0.23, a.u., mean ± s.e.m.; n=6) (Figure 2d,e). These 
findings suggest that HFS strengthens GABAergic transmission by increasing the response 
probability to minimal stimulation. 
 
Figure 2. Increase in induced IPSCs of small amplitude at the stellate interneurons following high 
frequency stimulation. 
(a) Evoked IPSC amplitude (-pA) recorded over time (s). Each black dot represents single evoked IPSC. 
Left, evoked IPSCs during the 5-minute-long control minimal stimulation (MS) recording before the 
HFS. Right, evoked IPSCs during the last 5 minute MS recording after the series of HSF. (b) Examples of 
raw traces of evoked IPSCs obtained during the control MS recording (left) and after the series of HFS 
(right). (c) Average amount of failures of evoking IPSCs decreased after the series of HFS. (d,e) 
Normalized average amplitude under 200 pA increased after the series of HFS (d) and normalized 
average amplitude over 200 pA did not change (e). (c,d,e) Open colourful circles show the data before 
and after HFS for single cells, Black closed circle is the average value. 
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Attenuating effect of NAC on the high-frequency induced strengthening of GABAergic 
transmission in stellate interneurons 
 
To address the question whether the increased response probability is due to a postsynaptic 
mechanism and might depend on increased mROS production, the antioxidant N-Acetyl-
Cysteine (NAC) was applied via the recording patch-clamp electrode. As expected based on the 
previous experiments in stellate interneurons (Accardi et al., 2014), NAC attenuated the effect of 
HFS in the recorded cells. There was no significant difference between the response failure rate 
before and after the series of HFS (42.9 ± 9.3%, and 44.7 ± 9.4%, respectively, mean ± s.e.m.; 
n=7, P=0.829, paired, two-tailed Student’s t-test) (Figure 3c). Normalized amplitude under 200 
pA did not change towards the end of the experiment (0.87 ± 1.6 a.u., mean ± s.e.m.; n=7) 
(Figure 3d). However, the average amplitude of responses larger than 200 pA was increased by 
the end of the recording (1.65 ± 0.27 a.u. mean ± s.e.m.; n=5) (Figure 3e). 
 
Figure 3. Attenuating effect of NAC on the high-frequency induced increase of induced IPSCs in 
stellate interneurons. 
(a) Evoked IPSC amplitude (-pA) recorded over time (s) during the internal perfusion with 1 mM NAC. 
Each black dot represents single evoked IPSC. Left, evoked IPSCs during the control MS recording 
before the HFS. Right, evoked IPSCs during the last 5 minute MS recording after the series of HSF. (b) 
Examples of raw traces of evoked IPSCs obtained during the control MS recording (left) and after the 
series of HFS (right). (c,d) Average amount of failures of evoking IPSCs and normalized average 
amplitude under 200 pA did not differ before and after HFS. (e) Normalized average amplitude over 200 
pA increased after the series of HFS. (c,d,e) Open colorful circles show the data before and after HFS for 
single cells, black closed circle is the average value. 
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The later effect might be due to an unrelated effect of NAC in the recorded cells. These results 
confirm that HFS-induced strengthening of GABAergic transmission is due, at least in large part, 
to a postsynaptic mechanism. 
HFS promotes the occurrence of slowly decaying evoked IPSCs 
α3-GABAARs were shown to be principal mediators of GABAergic synaptic strengthening 
induced by mROS in stellate interneurons (Accardi et al., 2014). These receptors are 
characterized by their slow decay kinetics compared to α1-GABAA receptors, which represent 
the majority of GABAA receptors present in stellate cells. We compared the decay kinetics of the 
IPSCs evoked by minimal stimulation at the beginning of the recording and after the series of 
HFS. The decay phase of each IPSC was fitted with a single exponential function and the value 
was plotted in function of the event amplitude (Figure 4). HFS triggered the emergence of a 
population of IPSCs with slower decay kinetics. Average decay kinetics was significantly slower 
after the series of HFS. As seen from the distribution, the respective decay kinetics values 
corresponded to the events with low amplitude (Figure 4a) (12.8 ± 0.3, before and 21.2 ± 0.6 ms 
after the HFS; mean ± s.e.m, P < 0.0001, paired, two-tailed Student’s t-test). Following 
application of NAC via the recording electrode, the decay kinetics of IPSCs before and after the 
HFS was not significantly different) (12.7  ±  0.4, before and 18.1± 0.6 ms after the HFS; mean ± 
s.e.m, P=0.04, paired, two-tailed Student’s t-test) (Figure 4b), strongly suggesting that the 
effects of HFS on the induction of IPSCs with low amplitude and slow kinetics, typical of a3-
GABAAR-mediated events, involve mROS production. 
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Figure 4. Slow decay kinetics of high-frequency stimulation induced IPSCs at stellate interneurons. 
Scatter plots of decay kinetics and evoked IPSCs amplitude before HFS (left, closed circles) and after the 
series of HFS (right, open circles) in (a) control conditions and (b) during the internal perfusion with 
1mM NAC. 
 
Heterogeneity of postsynaptic responses induced by repeated HFS in stellate interneurons 
The majority of the recorded cells showed a decrease in response failure to minimal stimulation 
following repeated HFS (8 of 14).  
 
However, the remaining six cells exhibited different responses to HFS (Figure 5). Half of them 
did not show a change in failure rate (51.6 ± 5.4%, before and 53.39 ± 5% after the HFS, mean ± 
s.e.m.; n=3, P=0.821, paired, two-tailed Student’s t-test) and average amplitude (normalized 
average amplitude at the end of the experiment: 0.93 ± 0.1 a.u., mean ± s.e.m.; n=3) of evoked 
IPSCs by the end of the recording (Figure 5a). The other half showed over 2.5-fold increase in 
response amplitude after the first HFS (normalized average amplitude at the end of the 
experiment: 2.7 ± 0.7 a.u., mean ± s.e.m.; n=3). Average response failure rate decreased in the 
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Figure 5. Different phenotypes of responses evoked by high-frequency stimulation in stellate 
interneurons. 
(a) Example of stellate interneuron not affected by HFS. (b) Examples of stellate interneurons with abrupt 
response to HFS. (a,b) Upper row, evoked IPSC amplitude (-pA) recorded over time (s) before and after 
HFS. Lower row, raw traces of MS recording before and after HFS. (c) Failure rate (left) and normalized 
average amplitude (right) of evoked IPSCs did not change before and after HFS in the non-responding 
group of cells. (d) Normalized average amplitude (right) of evoked IPSCs significantly increased after 
HFS and failure rate of the evoked IPSCs (left) decreased after the HFS. (e,f) Decay kinetics of evoked 
IPSCs of non-responding (e) and abruptly responding (f) group of interneurons before (closed circles) and 
after (open circles) HFS.  
 
course of experiment, but not significantly due to high variability within this group of recorded 
cells (29.4 ± 21.7%, before and 11.0 ± 8.1% after the first HFS, mean ± s.e.m.; n=3, P=0.471, 
paired, two-tailed Student’s t-test). Difference in the effects of HFS might be related to the type 
of the presynaptic partner cells activated by the minimal stimulation protocol, and therefore 
reflect GABAergic synapse heterogeneity in the molecular layer.  
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Insulin induces GABAergic synapse strengthening 
Insulin application was previously shown to increase cytosolic ROS in mouse cerebellum and 
induce GABAergic synaptic strengthening at the cerebellar granule cells (Accardi et al., 2015). 
We applied insulin extracellularly to explore whether it also has the potential to strengthen 
GABAergic synapses in stellate cells. We performed whole cell patch clamp recordings of 
GABAergic mIPSCs in stellate interneurons in wild-type mice under control conditions and 
following the application of 0.5 μM insulin into the bath solution after the first 5 minutes of 
recording. The cells were recorded for up to 30 minutes after the insulin wash in (Figure 6a,b,c). 
In the absence of insulin, there were no significant differences in the number (average counts at 
first 606 ± 133 and last five 599 ± 136, mean ± s.e.m.; n=8, P=0.887, paired, two-tailed 
Student’s t-test) and distribution of mIPSCs during the first and last five minutes of recording. 
#numerical values of average amplitudes of distinct response populations# (Figure 6a’,d).  
 
Insulin application led to a significant increase in the number of mIPSCs at the end of the 
recording (average counts at first 590 ± 146 and last five 762 ± 178, mean ± s.e.m.; n=7, 
P=0.004, paired, two-tailed Student’s t-test) emergence of a low amplitude population of 
mIPSCs (Figure 6b’,d). Since previous research showed that mROS induced the recruitment of 
α3-GABAAR mediating low amplitude (and slow kinetics) mIPSCs, (Accardi, 2014) we recorded 
mIPSCs in stellate interneurons of α3-KO mice in the presence of insulin in the bath solution. 
The recordings at the beginning and at the end of the experiment showed no significant 
difference in the number (average counts at first 211 ± 42.5 and last five 246 ± 60, mean ± 
s.e.m.; n=4, P=0.386, paired, two-tailed Student’s t-test) and distribution of the recorded (Figure 
6c’,d). Taken together, our findings suggest that postsynaptic strengthening of GABAergic 
transmission by insulin and HFS involve the recruitment of a3-GABAARs via an mROS-
dependent mechanism.  
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Figure 6. Insulin induces GABAergic synapse strengthening. 
(a) mIPSCs recorded from the same stellate interneuron in the beginning and the end of recording period 
showing that frequency and amplitude are similar throughout.  (a’) Amplitude distributions of mIPSCs 
recorded at the beginning (0-5 minutes) and at the end (30-35 minutes) of the recording. (b,c) Example 
traces of Inhibitory events from the same interneuron at the first and last 5 minutes of recording during 
insulin perfusion in WT (b) and α3-KO mice (c) . (b’, c’) Amplitude histograms comparing data before 
and after insulin application in WT (b’) and α3-KO mice (c’). 
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Discussion 
This study advances our understanding of mROS-induced inhibitory synaptic strengthening. We 
showed that a pool of GABAARs can be unsilenced under specific conditions. Because metabolic 
demand of a cell is reflected in mROS production, we used high frequency stimulation (HFS) to 
un-silence inhibitory synapses. We recorded evoked IPSCs using minimal stimulation approach 
before and after a series of HFS. In the majority of recordings, repeated HFS promoted an 
increase of frequency of evoked IPSC (Figure 2).  
Events evoked by HFS have slower decay kinetics (Figure 4a), suggesting based on previous 
findings (Accardi et al., 2014), it is α3 containing GABAARs that mediate this process and the 
effect is thus likely postsynaptic. Same setting recordings in α3-KO mice would be the next 
crucial experiment to confirm this conclusion.  
Another piece of evidence suggesting that this mechanism of synaptic strengthening is 
postsynaptic is the attenuation of HFS effect by the antioxidant NAC when introduced in the 
recording pipette (Figure 3). NAC was previously shown to antagonize the effect of antimycin 
on mROS-induced increase in mIPSCs in stellate cells (Accardi et al., 2014). The decay kinetics 
of IPSCs pre- and post-HFS evoked events did not differ with NAC present in pipette (Figure 
4b). This once more suggests a postsynaptic mechanism with mROS being an important player 
in the cascade of events leading to this type of inhibitory strengthening.  
GABAergic synaptic strengthening can occur postsynaptically via several mechanisms. 
GABAAR phosphorylation by multiple kinases (PKC, CaMKII, PKA, etc) can influence channel 
function or binding to trafficking molecules (Kittler and Moss, 2003). For example, PKC 
activation is known to induce dynamin-dependent endocytosis of gamma subunit containing 
GABAARs (Herring et al., 2005). The number of GABAARs on cell surface can be controlled by 
direct insertion of the receptors into the membrane and lateral diffusion at the synaptic 
membrane surface (Bogdanov et al., 2006, Bannai et al., 2009). 
Using different kinase blockers in the recording pipette would be necessary to identify kinases 
that are involved in this pathway. It still remains unresolved whether mROS-induced 
strengthening occurs via lateral diffusion or direct insertion into the postsynaptic sites. 
The majority of cells responded to HFS with an increase in occurrence of evoked IPSCs. There 
were two other smaller populations that either did not respond to the stimulation or responded 
that in an exaggerated manner (Figure 5). Differences in responses could be accounted for 
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variability in age and developmental stage of a stellate interneuron. Younger and less innervated 
stellate cells are located in the uppermost part of the molecular layer. It can be argued that 
populations of non-responding or “abruptly” responding cells could be in their maturation stages, 
still not being adequately integrated in the neuronal circuits. We did not find a correlation 
between the age of the animals and the recordings of specific types of responses. Taking this into 
account, we suggest that this response heterogeneity to HFS is due to the predominance of 
synaptic inputs from certain postsynaptic partners on possibly different subtypes of stellate 
interneurons or by predominant activation of presynaptic fibers originating from a specific type 
of presynaptic cell. Stellate cells receive inhibitory inputs from other stellate interneurons, 
basket, Lugaro and Golgi cells (Fritschy and Panzanelli, 2006). Specific presynaptic partners of 
different stellate cells could form synapses that are dominated by a certain subunit specific 
GABAARs. For instance, non-responding stellate cells could represent a population of stellate 
interneurons or a group of activated synapses that are dominated by α1-GABAARs. In contrast, 
“abruptly” responding synapses could represent a population that is dominated by α3-GABAARs. 
In our setting it was not possible to distinguish the exact input fibers we stimulated during the 
recordings. The effect on the cells that we saw during the specific recordings could depend on 
the type of fibers in the vicinity of the stimulating electrode. It could also reflect the density of 
innervation of a specific stellate cell. Possibly, if the density of innervation is low, HFS would 
fail to elicit the production of mROS.  
To explain the origins of this heterogeneity requires further experiments. It can be speculated 
that those cell where the strengthening was observed have higher levels of α3-GABAARs 
expression, than those neurons that did not show any change in evoked responses. Some 
synapses might be lacking specific machinery that mediates mROS-induced strengthening. 
Previous synaptic activity could influence the amount of α3-GABAARs filled vesicles, ready for 
endocytosis upon another high frequency input. To validate this assumption we need to identify 
presynaptic partners of stellate cells. It is not yet resolved which inhibitory inputs converge on 
one stellate cell. Paired (pre and postsynaptic partners recorded simultaneously) patch clamp 
recordings with pharmacological compounds are further planned to clarify this. It would be 
necessary to pharmacologically isolate specific inputs onto stellate cells. Silencing other stellate 
cells input with endocannabinoids (Kreitzer et al., 2002) could already reveal if there are other 
inhibitory inputs onto the stellate cells. Golgi cells can be fluorescently labeled, since they 
exclusively express glycine transporter 2 (GlyT2). Labeling would make it possible to identify 
Golgi cells within the granule cells layer.  
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We went further into looking at the triggers that through mROS elevation can strengthen 
inhibitory synapses at the stellate cells. Insulin was shown to elevate mROS. Previous data from 
cerebellar granule cells (Accardi et al., 2015) showed that insulin via increasing mROS can lead 
to α6-GABARs mediated synaptic strengthening. We showed an increase in small amplitude 
mIPSCs and the absence of this effect in α3-KO mice, proving that this strengthening is 
mediated by α3-GABAARs (Figure 6).  
The abundance and complexity of interaction between various types of interneurons within the 
cerebellar circuits is crucial in shaping the activity of Purkinje neurons that provide major 
cerebellar output. Inhibitory plasticity at the cerebellar interneurons fine-tunes cerebellar output 
with accordance to the activity within the network. mROS induced recruitment of GABAARs to 
synapses may act as an internal protective feedback mechanism, activated as a result of 
increasing excitatory inputs, that may trigger oxidative stress. mROS-induced inhibitory 
strengthening is so far described in both stellate and granule interneurons in the cerebellum and it 
could be a universal wide-spread feedback occurring in other types of neurons in different brain 
regions. The dysfunctions of this mechanism could have detrimental consequences on the firing 
of individual neuronal subpopulations and on the overall network activity.  
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IV. GENERAL DISCUSSION 
The overall objective of this thesis was to contribute to the understanding of the pathophysiology 
of neurodegenerative disorders by studying a wide range of mechanisms that could lead to them. 
Specifically, we investigated commonalities between Alzheimer’s disease and epilepsy, which 
have in common an activation of the immune system, neuronal and synaptic dysfunction, and 
altered adult neurogenesis. 
Contribution of induced seizures to AD-like pathology 
 
In the first study, we investigated how induced epileptic activity contributes to the development 
of AD-like pathology in AD-susceptible brain. We explored the effects of seizures in two AD 
mouse models, starting with a sporadic AD mouse model. In this model, PolyI:C-induced 
dysregulation of the immune system during fetal stages, predisposes the mice to developing AD-
like pathology after a second immune insult in adulthood ( “double hit” mouse model) (Krstic et 
al., 2012). Our goal was to find out whether in such immune challenged mice induced chronic 
recurrent seizures could substitute an adult immune insult possibly through associated 
inflammation, and similarly lead to the development of AD-like pathological hallmarks. Next, 
we wanted to see whether mice that have persistent epileptic activity could develop AD-like 
pathology, upon an immune challenge in adulthood. Both groups of experimental animals were 
left to age until 9 and 15 months, before being immunohistochemically analysed for AD-like 
phenotypes. We did not observe any significant differences between groups of animals and 
controls in both experimental settings. Neither prolonged seizures in immune-challenged mice 
nor an immune challenge in epileptic mice aggravated AD-like pathology with ageing. These 
studies showed that inflammation associated with the KA lesion, persists even a year after the 
injection. This finding suggests that the immune responses evoked by PolyI:C might be unique in 
their ultimate effect on abnormal protein aggregation.  
Apart from sustained microglial activation that spatially coincides with neurodegeneration in 
CA1, CA3 and the hilus, our group has shown that the KA-lesioned hippocampus is being 
populated by T lymphocytes. Furthermore, macrophage-like cells were detected in the dentate 
gyrus and their number positively correlated with the magnitude of granule cells dispersion. 
Unexpectedly, mice that lack T- and B-cells do not have a latent phase before onset of SRS and 
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their KA lesions are more severe due to infiltration of neutrophils. Depletion of peripheral 
macrophages prior to KA injection led to severe neurodegeneration of granule cells in the dentate 
gyrus. These findings suggest that T-lymphocytes and macrophages play a neuroprotective role 
in this TLE model  (Zattoni et al., 2011). The mechanisms of KA-induced inflammation differs 
from PolyI:C challenges. Recruitment and neuroprotective action of T-lymphocytes specific for 
KA-induced inflammation could be one of reasons why the development of AD pathology was 
not observed in our experiments.  
Although it is a logical conclusion from these results, it should be taken with some caution. 
There are a number of differences between the original “double hit” experiment (Krstic et al., 
2012 (Krstic et al., 2012) and our own experiments. These differences might underlie the 
absence of the expected effects of PolyI:C treatment combined with chronic seizures. For 
instance, the mouse strain used in our experiments (C57Bl/6JOla) differs from the original 
C57Bl/6JRcc one. C57Bl/6JOla carries a spontaneous mutation that prevents α-synuclein 
expression. α-synuclein is a presynaptic protein abundant throughout the brain. α-synuclein is 
known for its role in Parkinson’s disease (PD) pathology (Stefanis, 2012).  Interestingly, α-
synuclein was linked to the peripheral immune system and plays a role in some immune system 
related dysfunctions in PD (Kim et al., 2004). Taking into account the role of α-synuclein in the 
peripheral nervous system it is fair to assume that it’s absence could influence the outcome of the 
PolyI:C challenge.  
It is well known that stress caused by transportation increases the production of glucocorticoids 
in rodents (Landi et al., 1982). Glucocorticoids are widely used as to suppress inflammation 
(Cain and Cidlowski, 2017).  It was shown that following transportation corticosterone can 
remain elevated in mice for up to 4 days (Tuli et al., 1995). For the original “double hit” study no 
transport was needed, since mice were bred in house (Krstic et al., 2012). For the current project 
pregnant dams were shipped to our animal facility at GD14 and were left to adjust to the new 
conditions for 3 days. It is therefore possible that mice would have needed more time to recover 
and acclimatize after transportation.  In addition, such factors as litter effect, housing, injection 
procedures or handling represent additional variables that might have interfered with PolyI:C 
effects in our experimental setup.  In the absence of a positive control that PolyI:C treatment 
“worked” like in the experiments from (Krstic et al., 2012), our current findings remain 
inconclusive. 
In the second major part of this project, we tested whether chronic recurrent seizures in 
transgenic familial AD mice affect age-dependent AD pathology. ArcticAβ mice, which 
General Discussion 
77 
overexpress hAPP with two FAD mutations, start developing Aβ plaques after the age of 7 
months (Knobloch et al., 2007). At 2 months of age, still at pre-plaque stage, ArcticAβ mice 
were intracranially injected with KA to induce life-long SRS. AD mice were hypersensitive to 
KA and had increased mortality rate within the first 24h post-KA injection in comparison to WT 
controls. To prevent their immediate death during KA induced status epilepticus, animals were 
given a single dose of diazepam after the surgery. Although diazepam treatment prevented 
mortality within the first 24h, more than a half of the injected animals died within 2 months post-
injection. Intracellular Aβ levels are already increased at the age when mice receive KA 
injection. This fact suggests that the hypersensitivity to KA might be due to the early pre-plaque 
AD-related pathology. Brain tissue of the KA-injected ArcticAβ mice that survived 6 months 
after KA injection had a “mild” KA-lesion phenotype with usually only CA1 degeneration in the 
ipsilateral dorsal hippocampus. In comparison, only a few WT mice also had “mild” lesions 
indicating some degree of variability in the effects of KA, probably due to technical reasons. 
Therefore, it is conceivable that the ArcticAβ mice that died during ageing had more severe 
lesions causing a fatal status epilepticus. We did not investigate here the causes of the increased 
susceptibility of ArcticAβ mice to seizures, because this was part of a separate research project 
in our laboratory. 
In ArcticAβ mice, Aβ oligomers start to accumulate intraneuronally at the age of 3 months. 
Progressive accumulation continues with ageing to peak between 7 and 15 months. The first 
plaques, extracellularly and around blood vessels appear at the age of about 6 months. At 3 
months, the transgenic animals have increased pain sensitivity, as detected in the hotplate test, 
and strong locomotor and exploratory hyperactivity. This hyperactivity disappears with age. 
Starting after the age of 6 months, ArcticAβ develop anxiety and start performing significantly 
worse in an array of cognitive tests in comparison to their WT littermates (Knobloch et al., 
2007).  Our results show that increased sensitivity to seizure-inducing agents precedes cognitive 
impairments in ArcticAβ mice and coincides with the beginning of progressive accumulation of 
intracellular Aβ oligomers. Intraneuronal soluble Aβ oligomers are suggested to be more 
neurotoxic than insoluble forms. Intracellular Aβ oligomers were shown to be responsible for 
synaptic dysfunction, as they are often found associated with atypical dendrites with abnormally 
stacked membranes and non-functional cytoskeletal organelles (Takahashi et al., 2002, Oddo et 
al., 2003, Umeda et al., 2011). Aβ-related synaptic dysfunction that occurs early in this 
transgenic model could contribute to the increased sensitivity to KA.  
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To estimate the effect of induced seizures on the development of AD pathology we quantified 
the amount of Aβ plaques in 9 months-old KA- or vehicle-treated ArcticAβ mice. Contrary to 
our original expectations, the KA-lesioned ArcticAβ animals had reduced plaque pathology. In 
particular, in comparison to NaCl-injected ArcticAβ controls, KA-lesioned mice had 
significantly fewer plaques in the hippocampus. There was a significantly smaller number of 
Aβ plaques in the ipsilateral vs contralateral KA-injected hippocampus. A tendency towards 
decreased plaque load was observed in the neocortex of KA-injected vs NaCl-injected transgenic 
mice.  
Subcortical innervation was previously hypothesized to be involved in the initial seeding of toxic 
Aβ species (Braak and Del Tredici, 2013). The hippocampal formation receives extensive 
noradrenergic and serotonergic innervation from the locus coeruleus and upper raphe nuclei 
respectively. It turned out that the KA lesion does not lead to atrophy of these monoaminergic 
inputs in the hippocampus of ArcticAβ mice. Therefore, the reduced plaque pathology likely had 
another origin.  
Interestingly, at the age of 9 months, a sustained microgliosis was still present in the ipsilateral 
hippocampus in the WT KA-lesioned mice, but was restricted only to the degenerated CA1 
region in the KA-injected transgenic AD mice. The consequences of the KA insult, such as 
neurodegeneration, sustained immune response and SRS seem to prevent or delay the formation 
of Aβ plaques locally. The plaque load in the neocortex was not significantly different between 
KA-and NaCl-injected AD mice, which suggests that the group of the animals that survived until 
the age of 9 months was not simply consisting of the animals with reduced “baseline” plaque 
pathology.  However, it would be interesting to look at the extent of the AD-like pathology at the 
later time points to see whether the formation of plaques in this group of animals is temporally 
delayed.   
Reduced gamma rhythm was reported in several FAD mouse models (Stam et al., 2002, Palop et 
al., 2007, Verret et al., 2012b, Gillespie et al., 2016). Recently, it was shown that induction of 
fast-spiking parvalbumin-positive interneurons at gamma (40Hz) frequency decreased 
production of Aβ and triggered changes in gene expression in microglia, that results in its 
“engulfing” state (Iaccarino et al., 2016). It could be speculated that the reduced amount of Aβ 
plaques in our model is due to prolonged increased network activity that includes oscillations in 
gamma range as a component.  
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In fact, it was shown that gamma frequency oscillations (30–80 Hz) are present during the 
chronic period in the KA rodent model and that they actually precede the occurrence of 
spontaneous seizures (Bragin et al., 2005). “Mild” KA lesion phenotype in ArcticAβ mice 
implies preservation of CA3 region. Gamma activity occurs in the hippocampal CA3 in mice 
with KA-induced chronic seizures and the discharge frequency of oriens lacunosum-moleculare 
(OLM) interneurons changes from theta to gamma frequency band in this epileptic mice model 
(Dugladze et al., 2007). Bath application of KA onto brain slices of WT mice can induce gamma 
oscillations in CA3 (Hajos et al., 2000, Lu et al., 2011). It was suggested that alterations in 
intrinsic firing properties of interneurons underlie changes in the rhythmogenesis.  
Neurogenesis in AD predisposed brain  
In an attempt to explain sensitivity of ArcticAβ mice to KA, we characterized their pattern of 
adult neurogenesis. Abnormal adult neurogenesis affects seizure susceptibility in some of 
epilepsy mouse models. Suppression of adult neurogenesis increases the effect of KA in mice 
(Iyengar et al., 2015). Contrary to this finding, it was also shown that reduced adult neurogenesis 
reduces seizures in the pilocarpine mouse model of TLE. In AD mouse models, adult 
neurogenesis is frequently affected (Sun et al., 2009, Biscaro et al., 2012, Bonds et al., 2015). 
BrdU labeling in ArcticAβ mice revealed higher proliferation rates, but decreased survival of 
progenitor cells in the hippocampal DG. eGFP viral labeling of newborn neurons showed 
decreased dendritic arborization and decreased spine density in immature adult born neurons of 
transgenic mice. ArcticAβ mouse line is among those FAD models that overexpress mutant 
human APP. Those mouse models tend to have increased NPC proliferation, which can be 
related to the presence of high quantities of soluble APPα (sAPPα), a proteolyte of APP cleavage 
by α-secretase. sAPPα is a proliferation factor of adult progenitor cells (Demars et al., 2011, 
Demars et al., 2013). Early upregulation of intracellular, potentially harmful, Aβ species could 
be the reason for delayed maturation of the adult born neurons.   
Although ArcticAβ mice had increased NPC proliferation in comparison to WT littermates, the 
survival of these cells was decreased and there was no difference in cell fate of NPCs. Eventually 
this “equalized” the number of newborn neurons between the genotypes. Impaired maturation of 
newborn neurons could potentially lead to impaired development and integration within the 
network.  It was shown that adult-born neurons have a net inhibitory effect on the DG-CA3 
network (Acsady et al., 1998). Apart from affecting cognitive performance, weakening this effect 
on networks within the hippocampus could contribute to high sensitivity of ArcticAβ to KA. 
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Inhibitory transmission in neurodegenerative disorders 
GABAergic interneurons comprise a diverse family of cells that can play an important role in 
pathophysiological mechanisms of both AD and epilepsy. Their basic biological function is to 
control and synchronize the activity  of principal excitatory neurons and other interneurons, by 
which they participate in sustaining oscillatory network activity and network synchrony (Buzsaki 
(Buzsaki and Draguhn, 2004, Kepecs and Fishell, 2014). Numerous subtypes of inhibitory 
GABAergic interneurons control network synchrony and oscillatory brain rhythms (Buzsaki and 
Draguhn, 2004). Some interneurons fire rather tonically, independent of brain states (Sohal et al., 
2009, Lapray et al., 2012). Abnormalities in interneurons have been reported for many brain 
dysrhythmias and cognitive dysfunctions associated with various neurological conditions (Verret 
et al., 2012b, Hunt et al., 2013, Southwell et al., 2014, Tong et al., 2014). Cognitive deficits 
typical for AD, mechanisms of which rely on interneuron function, are described in TLE patients 
(Jokeit and Ebner, 1999, Sinforiani et al., 2003, Ito et al., 2009b). Altered gamma oscillation has 
been described in AD patients and in AD mouse models (Palop et al., 2007, Verret et al., 2012b, 
Gillespie et al., 2016). Parvalbumin (PV)-positive interneurons (Lapray et al., 2012, Verret et al., 
2012a, Kemere et al., 2013). 
In the second major part of the thesis, we focused on investigating a mechanism of synaptic 
strengthening recently described in cerebellar stellate interneurons. In the cerebellum, stellate 
cells inhibit Purkinje cells on their dendrites and by this contribute to controlling the action 
potential firing rate of Purkinje neurons.  Specifically, it was shown that mitochondrial-derived 
reactive oxygen species (mROS) do not only contribute to negative effects of oxidative stress, 
but actually have a physiological signaling function. mROS elevation leads to strengthening of 
inhibitory transmission in stellate cells by recruiting a population of GABAARs to the synapse, 
which differ in subunit composition compared to the resident GABAARs (Accardi, 2014). 
Cerebellar stellate cells mostly express α1 subunit-containing GABAARs. Increase in 
intracellular mROS triggers emergence of postsynaptic events with unique kinetic properties, 
that in stellate cells correspond to α3 subunit-containing GABAARs. Increase in mROS 
production is a reflection of cellular metabolism. Stellate interneurons use mROS as a distinctive 
indicator of the need to decrease firing in a response to a stimulus that could potentially lead to 
the oxidative stress.  mROS-dependent inhibitory synaptic strengthening was also shown in 
cerebellar granule cells. Elevation of mROS triggered recruitment of α6 subunit-containing 
GABAARs and as in case of stellate cells, had no effect on resident α1 subunit-containing 
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GABAARs. Interestingly, insulin probably by elevating mROS also triggers this strengthening, 
but the underlying signaling cascade activated by insulin remains to be determined. 
Cerebellar granule cells are excitatory glutamatergic neurons, originating from a germinal zone 
distinct from stellate cells,. The fact that mROS-dependent synaptic strengthening is present in 
these two quite distinct cell types suggests that it might be an important common protective self-
feedback mechanism against oxidative stress possibly present in many other CNS neurons. One 
of the next steps would be to confirm this possibility with patch-clamp recordings in neurons in 
other brain areas, such as for instance the hippocampus. Breakdown or deterioration of such an 
important protective mechanism could be involved in many neurological disorders.  
This project focused on studying further this unique inhibitory plasticity. We drew parallels 
between glutamatergic silence synapses and mROS-dependent plasticity. We used minimal 
stimulation experimental approach to reveal un-silencing of inhibitory synapses. Before and after 
challenging a stellate cell with high frequency input stimulus we recorded evoked IPSCs.  In 
most of the cases after high frequency stimulation a new population of IPSCs emerged among 
the evoked events. Increase in frequency of those events points towards an increase of the 
presynaptic release probability. This effect was prevented by an antioxidant NAC present in the 
patch pipette, suggesting this plasticity is postsynaptic and mROS dependent. Slow kinetics of 
the newly emerged responses suggested it is α3-GABAARs mediated. Further crucial experiment 
is the confirmation of absence of this plasticity in α3-KO mice.  
Some of the cells that were recorded responded to series of HFS with either no increase in 
frequency of evoked events or with a drastic 2.5 fold IPSCs increase. We hypothesize that the 
difference of responses depends on the origin of fibers that were stimulated each time. Stellate 
cells receive inhibitory inputs from other stellate and basket cells, Lugaro, globular and Golgi 
cells (Fritschy and Panzanelli, 2014). We suggest that subunit specificity of GABA synapse 
depends on the identity of the presynaptic partner. For example, synapses where we did not 
observe increase of frequency of evoked events could represent α1-GABAARs predominant 
stellate to stellate type of connection and those with abrupt increase type of responses could be 
α3-GABAARs Golgi to stellate type of input. To prove this, patch clamp recordings of stellate-
stellate or Golgi-stellate pairs are planned. 
For finding future therapeutic targets it is important to dissect specific pathways and mechanisms 
of mROS-induced plasticity. For other types of inhibitory plasticity, multiple possible 
postsynaptic mechanisms were demonstrated (Gaiarsa et al., 2002). Regulated vesicular 
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insertion, or lateral diffusion of the receptors at the synaptic membrane surface (Bannai et al., 
2009) interference with channel properties via phosphorylation of receptors by multiple kinases 
(PKC, CAMKII, PKA) (Kittler and Moss, 2003). Gephyrin is a major scaffolding protein at 
inhibitory synapses. ROS signaling molecule nitric oxide (NO) can lead to S-nitrosylation of 
gephyrin. This can lead to a reduction of putative inhibitory synapses and weakening of the 
synaptic strength (Dejanovic and Schwarz, 2014). Taking this into account, we suggest that in 
mROS-dependent strengthening, gamma-aminobutyric acid receptor-associated protein 
(GABARAP), could play an important role. Using peptides that block interaction between the 
receptors and gephyrin or GABARAP would be important to understand scaffolding mechanisms 
behind this type of plasticity.  
We wanted to see whether other stimuli that potentially elevate mROS are capable of inducing 
mROS-dependent plasticity in stellate cells. Insulin was previously shown to elevate ROS 
through its receptor (Goldstein et al., 2005). Bath application of insulin has already been shown 
to induce inhibitory strengthening in cerebellar granule cells (Accardi et al., 2015). We went on 
to test whether this holds true for stellate cells. We recorded TTX insensitive miniature IPSCs 
(mIPSCs) before and after bath application of insulin and saw an increase of the events with slow 
decay kinetics. This was not observed in α3-KO mice, which again suggests that this plasticity is 
mediated by α3 - and not α1-GABAARs.  
Stimuli such as high frequency stimulation or insulin application in excess can induce drastic 
oxidative stress. mROS-dependent plasticity can be viewed as a protective internal feedback 
mechanism, activation of which causes inhibition and thus decreases metabolic need of the cell, 
preventing aggravation of oxidative stress. Mitochondrial dysfunction and oxidative stress are 
described in many neurodegenerative disorders, including AD (Islam, 2017, Mamelak, 2017). If 
mROS-dependent strengthening is indeed a universal mechanism throughout the brain it is fair to 
assume that hindering it will lead to abnormal neuronal firing and thus network dysfunction. 
Fine-tuning of interneuronal firing can be achieved through heterogeneity of GABAARs 
recruited to the synapses in response to overwhelming stimuli.  
In many neurological disorders, including AD and epilepsy, network activity responsible for 
cognition and memory encoding is altered already at pre-clinical stages (Sperling et al., 2009, 
Anticevic et al., 2012, Fahoum et al., 2013, Fahoum et al., 2014, Oser et al., 2014, Seidman et 
al., 2014). The alterations include activation and deactivation deficits, abnormal network 
oscillations and network hypersynchrony. In people predisposed to AD, network alterations 
occur decades before the diagnosis (Filippini et al., 2009, Bateman et al., 2012, Reiman et al., 
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2012). In healthy individuals during cognitive tasks that require attention, fMRI signals in 
specific brain areas are increased (for example hippocampus during memory encoding). So 
called default-mode networks (DMN) are activated during inwardly oriented network activity, 
such as daydreaming. During attention demanding tasks DMNs are deactivated (Raichle et al., 
2001, Boyatzis et al., 2014). Default networks are comprised of functionally distinct association 
areas (precuneus/posterior cingulate cortex, medial prefrontal cortex, medial, lateral and inferior 
parietal cortex) that interact with each other and with the medial temporal lobe (Greicius et al., 
2003, Greicius et al., 2004, Vincent et al., 2006, Buckner et al., 2008, Buckner et al., 2009). 
Interestingly, amyloid deposition measured by PiB-PET (Pittsburgh compound B-positron 
emission tomography – is used to image amyloid deposits in AD diagnosis) mostly accumulates 
in cortical regions involved in the default network (Klunk et al., 2004, Buckner et al., 2005) and 
these cortical areas have reduction of metabolism, functional disruption, and atrophy in early 
stages of clinically diagnosed AD and mild cognitive impairment (MCI) (Greicius et al., 2004, 
Rombouts et al., 2005, Celone et al., 2006, Sorg et al., 2007, Pihlajamaki et al., 2008). Impaired 
deactivation of DMNs during attention demanding tasks is observed in many pathological 
conditions (Sperling et al., 2009, Anticevic et al., 2012, Fahoum et al., 2013, Oser et al., 2014, 
Seidman et al., 2014). Before the emergence of the first obvious cognitive symptoms, individuals 
with cerebral amyloid deposits show hyperactivation of hippocampus (probably a compensation 
for early cognitive deterioration) and decreased DMN deactivation. Similar synchrony 
disturbances are observed in pre-symptomatic APOE ε4 (major risk factor for AD) gene allele 
carriers, FAD mutations carriers and patients with mild cognitive impairment (MCI) that 
eventually develop AD (Bookheimer et al., 2000, Dickerson et al., 2005, Celone et al., 2006, 
Trivedi et al., 2008a, Trivedi et al., 2008b, Filippini et al., 2009, Quiroz et al., 2010, Bakker et 
al., 2012, Reiman et al., 2012, Sepulveda-Falla et al., 2012, Kunz et al., 2015). 
Interestingly, disturbances in functional connectivity of DMN spatially overlap with amyloid 
deposits in AD patients (Hedden et al., 2009, Mormino et al., 2011, Mormino et al., 2012, 
Dennis and Thompson, 2014). Based on studies in primates, it has been suggested that DMN 
would exhibit less gamma power during execution of attention-demanding tasks than during 
resting baseline periods (Harris and Thiele, 2011). Precise mechanisms on cellular and network 
levels of the DMN generation are still not identified, but interneurons undoubtedly play an 
important role in this highly orchestrated synchronous activity. Various impairments in 
interneuron firing or synaptic function and plasticity could underlie impaired synchrony and 
deactivation of DMNs. Persistent activity in the DMN areas could trigger increased Aβ 
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production, which in turn would deteriorate synaptic function. mROS induced plasticity could 
potentially be a common mechanism of inhibitory strengthening in various interneurons and 
principal cells. This hypothesis has to be further investigated. Dysfunction of this plasticity could 
lead to network abnormalities and excessive oxidative stress, which could lead to extensive 
neuronal loss. mROS induced plasticity is a promising candidate for search of novel therapeutic 
targets.   
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ABBREVIATIONS 
5-HT 5-hydroxytryptamine 
ACh acetylcholine 
aCSF artificial cerebrospinal fluid 
AD,PD Alzheimer’s disease, Parkinson’s disease 
ADAM a disintegrin and metalloproteinase 
AMPA α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid 
APH-1 anterior pharynx-defective 1 
APOE apolipoprotein E 
APP amyloid precursor protein 
BACE beta-secretase  
BBB blood brain barrier 
BrdU bromodeoxyuridine 
CAA cerebral amyloid angiopathy 
CAMKII Ca
2+
/calmodulin-dependent protein kinase II 
CD68 cluster of differentiation 68 
ChAT   choline acetyltransferase 
CNS central nervous system 
DMN default mode network 
EEG electroencephalogram 
EPSC excitatory postsynaptic current 
GABA gamma-aminobutyric acid 
GABARAP gamma-aminobutyric acid receptor associated protein 
GD14/17 gestational day 14/17 
GFAP glial fibrillary acidic protein 
GFP green fluorescent protein 
GSK3-β glycogen synthase kinase 3 beta 
HFS high frequency stimulation 
IPSC inhibitory postsynaptic current 
KA kainic acid 
LMW/HMW  low molecular weight/ high molecular weight 
LPS lipopolysaccharide 
LTD long-term depression 
LTP long-term potentiation 
MCI mild cognitive impairment 
Abbreviations 
102 
mGluR metabotropic glutamate receptor 
mROS mitochondrial reactive oxygen species 
NAC N-Acetyl-Cysteine 
NFT neurofibrillary tangles 
NMDA N-Methyl-D-aspartate 
NPC neural precursor cells 
NSAID nonsteroidal anti-inflammatory drug 
PEN2 presenilin enhancer 2 
PET positron emission tomography 
PKA protein kinase A 
PKC protein kinase C 
PKCα/PICK1 protein kinase C α/ protein interacting with C kinase 1 
PolyI:C polyinosinic:polycytidylic acid 
PS1, PS2 presenelin 1, presenelin 2 
SRS spontaneous recurrent seizures 
SVZ subventricular zone 
TH tyrosine hydroxylase 
TLE temporal lobe epilepsy 
TLR toll-like receptor 
TNFα tumor necrosis factor alpha 
  
  
Hippocampal formation: 
 
 
CA1 cornu ammonis 1 
         sp         stratum pyramidale 
         sr         stratum radiatum 
         slm         stratum lacunosum-moleculare 
CA3 cornu ammonis 3 
         sl        stratum lucidum 
         sp        stratum pyramidale 
DG dentate gyrus 
         ml        molecular layer 
         gcl        granular cell layer 
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